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ABSTRACT 
 
Neuroblastoma (NB) is the most frequent malignant tumor in pediatric age derived 
from primitive cells of the sympathetic nervous system. It is composed of cells with 
different levels of neural differentiation and high tumor cell differentiation grade 
correlates with a positive outcome. Current NB treatments include surgery, the use of 
radio or cytotoxic therapies and the pro differentiating agents as retinoids to eradicate 
minimal residual disease (MRD). Nowadays there is no treatment that heals 
completely NB. Expression of the hypoxia inducible factors (HIFs) HIF1A and EPAS1 
and/or hypoxia-regulated pathways has been shown to promote the undifferentiated 
phenotype of NB cells. The first hypothesis of this study is that HIF1A and EPAS1 
expression represents one of the mechanisms responsible for the lack of 
responsiveness of NB to differentiation therapy.  
Clinically, high levels of HIF1A and EPAS1 expression were associated with inferior 
survival in two NB microarray datasets, and patient subgroups with lower expression 
of HIF1A and EPAS1 showed significant enrichment of pathways related to neuronal 
differentiation. In NB cell lines, the combination of all-trans retinoic acid (ATRA) with 
HIF1A or EPAS1 silencing led to an acquired glial-cell phenotype and enhanced 
expression of glial-cell differentiation markers. Furthermore, HIF1A or EPAS1 
silencing might promote cell senescence independent of ATRA treatment. Taken 
together, this data suggest that HIFs inhibition with ATRA treatment promotes 
differentiation into a more benign phenotype and cell senescence in vitro.  
Between HIFs, HIF1A is the most promising factor to be silenced to induce 
differentiation in cotreatment with ATRA. HIF1A protein expression is changeble 
inside solid tumors because of oxygen levels. The second intent of this study has 
been to indentify HIF1A target genes whose expression is activated or repressed by 
HIF1A regardless microenviroment. The expression of these “HIF1A target genes” 
will be related to all tumor area and their silencing might lead solid tumor to be easily 
wiped out. Transcriptome analysis of HIF1A silenced NB cell lines and in silico 
analysis have suggested putative HIF1A targets to be used in combination with ATRA. 
These findings open the way for additional lines of attack in the treatment of NB 
minimal residue disease. 
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1 BACKGROUND 
 
1.1 Neuroblastoma 
Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. 
The median age at diagnosis is ∼19 months, but rarely, there are cases 
observed in utero or in patients older than 19 years [1]. The incidence of NB is 
10.2 cases per million children under 15 years of age [2]. Tumors can arise 
anywhere along the sympathetic nervous system (SNS), with the majority 
occurring in the abdomen and are associated with the adrenal gland or 
sympathetic ganglia (Figure1). It is widely accepted, that the cell of origin for 
NB arises from the sympathoadrenal lineage of the neural crest during 
development. The neural crest is present only during embryogenesis and gives 
rise to several cell types including peripheral neurons, enteric neurons, glia, 
melanocytes, Schwann cells, cells of the craniofacial skeleton and adrenal 
medulla [3]. Cells arising in the adrenal medulla are postganglionic neurons 
that have lost their dendrites and axons. Preganglionic neurons from the 
central nervous system (CNS) connect directly to adrenal medulla cells and 
stimulate the release of catecholamines. Thus, the adrenal medulla is a 
ganglion of the SNS.  
 
Figure 1. Clinical Presenations of Neuroblastoma (American Society of Clinical Oncology 2005) 
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Similar to normal neuroblasts, NBs show variable amounts of differentiation 
along gangliocytic and schwannian lineages. In fact the undifferentiated form 
of NB can spontaneously differentiate in a less aggressive type such as the 
Ganglioneuroma or Ganglioneuroblastoma enriched in Schwannian stoma. 
The pathologic classification of the tumor is based on its differention grade, 
which reflectes the prognosis. For over a century, researchers observed that 
NBs exhibit diverse and often dramatic clinical behaviors. It accounts for 
disproportionate mortality among the cancers of childhood; but in the same 
time it is associated with one of the highest proportions of spontaneous and 
complete regression of all human cancers [4,5]. 
 
1.2 Staging 
NB is distinguished from other solid tumors by its biologic heterogeneity and 
range of clinical behavior. Diagnosis and staging criteria are based on the 
International Neuroblastoma Staging System (INSS) first published in 1988, 
that allowed physicians to determine treatment plans based on patient risk [6] 
(Table 1).  
 
Table 1 The international neuroblastoma staging system (INSS)  
 
Age and stage of disease are two criteria for risk classification. Children 18 
months old or older with stage 4 (metastatic disease) are at high risk for death 
from refractory disease. In contrast, infants younger than 12 months with 
localized tumors (stage 1-2) almost always cured, often without cytotoxic 
therapy. Molecular analysis is a critical step in risk stratification and clinical 
care planning for NB. The challenge has been to identify which children may 
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benefit from treatment reduction versus intensified therapies. INSS staging, 
used for more than 20 years, was influenced by the location of the primary 
tumor (e.g., intrathoracic versus abdominal primary), access to experienced 
pediatric surgery and pathology teams, and access to detailed radiographic 
imaging. To compensate these variables, the European International Society 
of Pediatric Oncology, validated a set of surgical risk factors based on 
radiographic characteristics, that could be used preoperatively to assess 
resectability and risk of developing postoperative complications [7]. These 
characteristics, renamed image-defined risk factors (IDRFs), are incorporated 
into the (International Neuroblastoma Risk Group Staging System/INRGSS). 
The INRG classification system includes INRG stage, age, histology, tumor 
grade, MYCN status, 11q alteration status, and DNA ploidy. Based on this, 
clinically different pretreatment groups were described as: very low, low, 
intermediate, and high-risk in terms of 5-year event-free survivals (Table 2).  
 
 
 
Table 2 International Neuroblastoma Risk Group (INRG) consensus pretreatment classification schema 
(Journal of Clinical Oncology 2009) 
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These risk groups can be used to assign treatment recommendations or 
assess a patient’s eligibility for participation in investigational studies [8]. 
Prospective implementation of the new INRG classification system will also 
allow improvements in collaborative efforts on international clinical trials. 
 
1.3 Genetic basis  
About thirty years of study on NB, some genetic alterations as prognostic factor 
of disease have been identified. The genetic aberration most consistently 
associated with poor outcome is genomic amplification of MYCN [9]. MYCN 
amplification occurs in roughly 20% of primary tumours and is strongly 
correlated with advanced stage disease and treatment failure [10]. Segmental 
chromosomal aberrations, most frequently found in 1p, 1q, 3p, 11q, 14q, and 
17p, are associated or not with MYCN amplification, and are observed in 
almost all high-risk and/or stage 4 NBs [11]. 
Furthermore, copy number changes of whole chromosomes are also 
commonly observed in NB, and are closely associated with the ploidy of the 
tumors. In most cases, karyotypes of NB cells are either in the diploid ('near-
diploid') or hyperdiploid ('near-triploid') range. These alterations have been 
associated with more favorable outcome if correlated to a younger age at 
diagnosis, and to lack of structural chromosomal aberrations of the patients 
[12,13]. 
Genome-wide association studies (GWAS) focused on single nucleotide 
polymorphisms (SNPs) that provided the basis for the identification of 
activating mutations in the Anaplastic Lymphoma Kinase (ALK) oncogene. 
These mutations appear to be responsible for most of the rare cases of 
hereditary NB, and might also be relevant for a smaller fraction (6-9%) of 
sporadic tumors [14,15]. 
GWAS studies have discovered common predisposing genetic variants, that 
are associated with tumor phenotype and NB susceptibility [16]. These findings 
suggest that genomic variation may underlie events that initiate tumorigenesis. 
Susceptibility to low-risk NB is associated with SNPs within DUSP12 (at 1q23), 
HSD17B12 (at11p11.2), DDX4, and IL31RA (both at5q11.2) and correlate with 
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less aggressive disease [17]. SNPs at FLJ22536, FLJ44180 (6p22), CASC15, 
CASC14, NEFL, BARD1, LM01, HACE1, and LIN28B have been found in DNA 
copy number variants of high-risk NB and also represent a source of genetic 
diversity [18-21]. Common variant polymorphisms may work additively to 
activate NB tumor initiation. Several of these DNA variations influence gene 
and protein expression to promote tumorigenesis and tumor progression. This 
is exemplified by compelling evidence in BARD1. It is the most significant 
genetic contributor to NB risk and may promote tumor growth and progression 
[22]. 
High throughput sequencing-based studies have highlighted that recurrent 
mutations of single genes are infrequent in primary NB with activating mutation 
in ALK and inactivating mutations in ATRX and TERT being the most frequent. 
In latest years mutations in RAS-MAPK signaling associated genes as NRAS, 
KRAS, HRAS, BRAF, PTPN11, and FGFR1 were detected in the relapsed 
samples and were absent in the samples at diagnosis [23-27]. These data 
suggest the oncogenic evolution of “low frequency” mutated genes from 
samples at diagnosis to relaps. The identification of somatic “driver mutations” 
raises a new challenge in the treatment of cancer that involves the use of a 
selection of therapies based on different genetic alterations in individual 
tumors. 
 
1.4 Therapy and Differentiation  
The biologic heterogeneity of neuroblastic tumors occurring in pediatric age 
leds to a disparity of used therapeutic approches. For tumors that have 
favorable biologic features, the clear trend has been to reduce therapeutic 
intensity. In contrast, the approach to tumors with adverse prognostic features 
has shifted toward an intensifying chemoradiotherapy and research of 
personalized cures [28]. 
The induction of differentiation seems one of the most promising approaches 
following cytotoxic treatment, in the minimal residual disease (MRD) therapy 
in high-risk NB patients. The beneficial effects of "differentiating treatment" are 
well-known in acute promyelocytic leukemia where the standard treatment 
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involves the use of All-Trans Retinoic Acid (ATRA) combined to 
chemotherapeutic agents [29].  
Retinoids are signal molecules that together with their nuclear receptors 
activate signals for embryonic development and for the maintenance of the 
differentiated tissue state through the regulation of cell proliferation, 
differentiation and death. Furthermore, they have a substantial role in 
development and on physiological functions of nervous and reproductive 
systems [30, 31]. 
The action of retinoids is undertaken through two receptor types, belonging to 
the nuclear receptor family of Steroid Hormones: RAR (Retinoic Acid 
Receptor) and RXR (Rexinoic Receptor). Both receptors are expressed in 
three isoforms denominated with α, β and γ, which differ from each other for 
the space-time distribution and the affinity of ligands. RAR and RXR are 
transcription factors that function mostly as RAR RXR hetero-dimers and the 
isomer all-trans RA (ATRA) is the main ligand and activator of RAR but not of 
RXR. Retinoids offer great potential in cancer therapy by their ability to induce 
cell differentiation. Indeed, it has been proved that retinoic acid and its 
derivates are able to iduce differentiation and reduce the growth of NB cells 
[32]. 
So far outcomes for patients with high-risk NB remain poor despite recent 
improvements observed in randomized trials. Treatment options include in first 
phase an induction therapy with intensive cycle of chemotherapeutic agents. 
Subsequently, patients follow a consolidation phase with myeloablative 
therapy and stem cell transplantation (SCT) and radiation therapy to primary 
tumor and residual metastatic sites. To treat potential MRD following SCT, 
patients undergoing a post-consolidation phase, which involves the use of 
neuronal differentiating agent as isotretinoin (13-cis retinoic acid) and antibody 
anti-GD2 combined with with interleukin-2 (IL-2)/granulocyte-macrophage 
colony-stimulating factor (GM-CSF) [33,34]. 
 
1.5 HIF-1 α e HIF-2 α (Hypoxia-Inducible Factor) 
It’s essential for the function and survival of aerobic organisms an adequate 
oxygen supply to cells and tissue. When oxygen supply fails to meet demand, 
it can occur a hypoxia condition. The definition of hypoxia is somewhat 
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ambiguous because normal oxygen pressure (PO2) varies between different 
tissues. For in vitro studies 1% oxygen is commonly used to mimic a hypoxic 
environment [35]. Tumor hypoxia is due to the formation of non-functional 
blood vessels in neoplastic tissue and poorly vascularized areas. Tumor cells 
in low-oxygenated areas grow faster and are associated with aggressive tumor 
phenotypes, treatment resistance, and poor clinical patient prognosis [36,37]. 
The cellular response to hypoxia is mediated by the hypoxia-inducible factors 
(HIFs), which regulate the expression of multiple genes involved in adaptation 
and progression of cancer cells. Each HIF transcription factors is formed of two 
subunits: the α-subunit and the β-subunit, both belonging to the basic helix–
loop-helix (HLH)-PER-ARNT-SIM (bHLH-PAS) protein family [38]. The α-
subunit is oxygen sensitive, while the β-subunit (HIF-1β or ARNT) is 
ubiquitously expressed. In the presence of oxygen, conserved proline residues 
on the α-subunit, are hydroxylated by prolyl-4-hydroxylases PHDs (a set of 
oxygen-, iron-, and ascorbate-dependent enzymes belonging to the 2-
oxoglutarate-dependent oxygenase superfamily) [39] and recognised from the 
von Hippel–Lindau (pVHL) tumor suppressor protein, that promotes its 
degradation via ubiquitin-proteasome pathway [40]. However, under hypoxia, 
PHDs cannot hydroxylate the α-subunit resulting in HIF-α protein stabilization, 
nuclear translocation, and dimerization with HIF-1β. There are three different 
α-subunit isoforms: HIF-1α, HIF-2α, and HIF-3α. HIF-1α (expressed by the 
HIF1A gene) and HIF-2α (expressed by the EPAS1 gene) have been most 
studied, whereas few is known about HIF-3α. HIF-1α is thought to mediate the 
acute response to hypoxia and HIF-2α is stabilized longer in time also at 
normal physiological oxygen levels [41]. 
HIFs expression are essentiantial for SNS development, indeed they are 
expressed in human embryonal and fetal SNS cells [42] and are important 
regulators of the synthesis and secretion of catecholamines [43,44], which are 
key SNS neurotransmitters. Several studies report that hypoxia and HIFs 
substained stem cell-like features in cancer cells making them more 
aggressive. 
It is important to mention that although low oxygen concentration is the major 
mode of HIFs stabilization, additional non-hypoxia-driven stimuli may also 
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regulate HIFs. Interestingly, factors such as nitric oxide [45], the cytokines 
interleukin-1beta (IL-1B), tumor necrosis factor α (TNF-α) [46], and trophic 
stimuli as serum and the insulin-like growth factors [47], might modulate HIFs 
up-regulation under normoxic conditions [48]. 
“Hypoxic” biomarkers such as HIF-1α and HIF-2α are associated with poor 
clinical prognosis in tumor patients. Tumor cells are also able to express these 
biomarkers under normoxic conditions [49] so they could be considered 
microenvironment independent prognostic factors for poor chemotherapeutic 
response and shortened patient survival time. 
 
1.6 Hypoxia and chromatin remodelling. 
Substantial evidences indicates that hypoxia induces epigenetic changes in 
the chromatin landscape, which consequently affect the transcriptional profiles 
of tissues. [50,51]. So far, it is not known how hypoxia generates chromatin 
changes. Interestingly, the stabilization of HIF-1α increases the expression of 
several histone lysine demethylases (KDM) which are crucial enzymes in the 
control of gene expression in hypoxia, but, with other chromatin modifiers, they 
can also affect heterochromatin structures, genome stability, and 
reprogramming of cellular senescence loci [52,53]. Histone demethylases 
control gene expression throw different mechanisms: they can enhance or 
repress the initiation of transcription, increase the rate of transcription 
elongation binding Pol II and remove methyl groups from the histones locati in 
gene bodies and recruit co-activators to the initiation complex in a 
demethylase-independent manner [54,55]. 
As previously mentioned, hypoxia is not the only reason that can stabilize the 
expression of HIFs. Interestingly, the expression of HIF1 can be stabilized by 
several other signals, mostly related to stress (Figure 2). It’s clear that HIF1A 
and its target genes are crucial keypoints in epigenetic reprogramming and 
that normoxia microenviroment rather than hypoxia should be dissected to 
deepen knowledge of molecular mechanisms driven by HIF1A in solid tumors.  
 
 
13 
 
 
Figure 2. Representative scheme of HIF-1 regulation. 
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2. AIM 
 
In NB cell lines, low oxygen tension might promote reductions in neuronal and 
neuroendocrine gene expression markers with the acquisition of an immature 
stem-like phenotype. The correlation between hypoxia and the grade of the 
differentiation status, suggests HIF and/or HIF-regulated pathways as one of 
the mechanisms behind the lack of cell responsiveness to differentiation 
therapy [56,57]. Therefore, inhibition of HIFs might provide more effective 
methods to enhance the NB cell propensity to differentiate. 
Several studies in vitro have shown that in human NB cell lines, the use of 
differentiating agents like all-trans retinoic acid (ATRA) and 13-cis retinoic acid 
can cause arrest of cell growth, and can also induce neuronal differentiation 
[58,59]. The first aim of this study was to asses whether the combination of 
HIF1A or EPAS1 silencing with ATRA treatment can provide major benefits 
over the use of the single agents. The proposed combination therapy can 
potentially help to reduce NB relapse through two main effects: differentiation 
into a more benign phenotype and induction of senescence. 
HIF-1α expression is changeble inside different areas of solid tumors because 
of oxygen levels. This feature makes it hardly targetable by the use of direct 
drug compound, as HIF1A antibody. For this purpose the second intent of this 
study is to identify HIF1A target genes whose expression is activated or 
repressed by the presence of HIF1A regardless microenviroment. The 
expression of these HIF1A target genes will be related to all tumor area and 
their silencing might lead solid tumor to be easily wiped out. 
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3. MATERIALS AND METHODS 
 
3.1 Microarray-KAPLAN SCAN.  
R2 web tool (http://r2.amc.nl) was used to predict the association of HIF1A, 
EPAS1 expression with survival of patients with NB. In brief, for each gene, R2 
calculates the optimal cut-off in the expression level to divide the patients into 
‘good’ and ‘bad’ prognosis cohorts. Samples within a dataset are sorted 
according to the expression of the investigated genes, and are divided into two 
groups. All of the cut-off expression levels and their resulting groups are 
analyzed according to patient survival. For each cut-off level and grouping, the 
log-rank significance of the projected survival is calculated. The best P value 
and the corresponding cut-off are selected. The cut-off level is reported and 
was used to generate the Kaplan-Meier curves. These depict the log-rank 
significance (raw P) as well as the P value corrected for multiple testing 
(Bonferroni correction) of the cut-off levels for each gene. Kaplan scan analysis 
was performed to estimate the overall survival and relapse-free survival 
according to HIF1A and EPAS1 in the two microarray datasets: the Seeger 
dataset that included 102 International Neuroblastoma Staging System stage 
4 patients without MYCN amplification; and the Versteeg dataset that included 
88 patients with different clinical characteristics. The same analysys were 
reproduced for FGFR1 FZD1 and SYT13.   
 
3.2 Correlation of genes involved in development and HIF1A and EPAS1 
mRNA levels.  
Differential expression of genes involved in development was tested between 
the two groups of patients divided according to their median values of 
expression of HIF1A and EPAS1. This analysis was performed using the R2 
web tool (http://r2.amc.nl) and the gene expression data of the Versteeg and 
Seeger datasets. The list of genes for both of these datasets is shown in 
appendices Table 7.1 and 7.2. The coefficient of correlation (R-value) between 
the gene expression values and the two subgroups (‘High’ and ‘Low’ HIF1A or 
EPAS1 espression) is also reported. The statistical differences in the gene 
expression values betweenthe patient groups with ‘High’ and ‘Low’ HIF1A or 
EPAS1 expression were evaluated by ANOVA tests implemented in the R2 
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web tool. The p-values were corrected for multiple testing according to the 
false discovery rate. The significant threshold was established at a false 
discovery rate of 30%. Kegg pathway analysis was independently performed 
on the two lists (appendices tables 7.1-7.2) of the significant genes obtained 
from the two datasets (i.e., Versteeg, Seeger). 
 
3.3 Cell culture.  
The human SHSY5Y, SKNBE2c, SKNAS and HEK293T cell lines were grown 
in Dulbecco’s modified Eagle’s medium supplemented with 10% heat-
inactivated fetal bovine serum (Sigma), 1 mM L-glutamine, penicillin (100 U/ml) 
and streptomycin (100 μ g/ml) (Invitrogen), at 37 °C, under 5% CO2 in a 
humidified atmosphere. The NB cells were plated at 60% to 70% confluence 
and treated with 5 μM and 10 μM ATRA (Sigma) dissolved in dimethyl 
sulfoxide. During the HIF1A and EPAS1 silencing and the ATRA treatments, 
the cells were grown under normoxic conditions. The cells under hypoxia were 
grown at 1% oxygen for 6 h. 
 
3.4 Production of lentiviral particles and infection of cell lines.  
To knock-down HIF1A and EPAS1 expression, the pGIPZ lentiviral shRNAmir 
that targets human HIF1A and EPAS1 were purchased from Open Biosystems 
(Thermo Fisher Scientific, Inc.). We used two different shRNAs for each gene. 
The shRNAs against EPAS1 were: V2LHS113750 (RHS4430-98894439) and 
V2LHS-113750 (RHS4430- 98851126). The shRNAs against HIF1A were: 
V2LHS_132152 (RHS4430-98513964) and V2LHS_236718 (RHS4430-
98513880). A non-silencing pGIPZ lentiviral shRNAmir was used as the control 
(RHS4346). HEK293T were transfected using 10 μg shRNA plasmid DNA, 30 
μl Trans-Lentiviral Packaging Mix (OpenBiosystem), and 25 μl TrasFectin (Bio-
Rad), in 10-mm plates. The supernatants (10 ml per condition) were harvested 
after 24 h, centrifuged at a low speed to remove cell debris, and filtered through 
0,45-μm filters. In-vitro transduction and determination of the lentivector titre 
were performer as reported previously [60]. After 48 h of incubation, the 
transduced cells were examined microscopically for the presence of 
TurboGFP expression (70%–90%). To obtain 100% GFP-positive cells, 
puromycin was added into the medium for an additional 10 days. The reported 
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data are representative of the experiments performed and confirmed using 
both lentiviral vectors for each gene. 
 
3.5 Fractionation of nuclear proteins and Western blotting.  
Cell pellets were resuspended in a hypotonic buffer (10 mM HEPES-K+, pH 
7.5, 10 mM KCl, 1.5 mM MgCl2, 0.5 M dithiothreitol) in the presence of a 
protease inhibitors cocktail (Roche). The cells were lysed by addition of ice-
cold 0.5% NP-40 for 10 min. The nuclei were pelleted at 1,000 x g for 2 min at 
4 °C. The nuclear pellets were washed twice with 0.2 mM EDTA, 1.5 mM 
MgCl2, 0.5 M dithiothreitol, 25% glycerol) with protease inhibitors. The nuclei 
were incubated on ice for 30 min and vortexed periodically. The supernatants 
containing the nuclear proteins were collected by centrifugation at 16,000 x g 
for 5 min at 4 °C. The protein concentrations were determined by Bradford 
assays (Bio-Rad). Thirty micrograms of protein were loaded and separated 
using 8% polyacrylamide gels, and transferred onto polyvinylidene difluoride 
membranes (Bio-Rad). The membranes were blocked with 5% non-fat dried 
milk (Applichem) in phosphate-buffered saline (PBS) with 0.2% Tween (PBS-
T) for 1 h, and then probed with anti-HIF-1α (610959; BD Biosciences) or anti-
HIF-2α (ab8365; Abcam) antibodies. After a wash in PBS-T, the membranes 
were incubated with horseradish-peroxidase-conjugated anti-mouse 
secondary antibody (1:4000 dilution; ImmunoReagent), and then the positive 
bands were visualized using the ECL kit SuperSignal West Pico 
Chemiluminescent Substrate (Pierce). A goat anti lamin-β antibody (1:100 
dilution; sc-6216; SantaCruz) was used as the control for equal loading. The 
protein band images were acquired with a GelDoc 2000 system (Bio-Rad), and 
the densitometry measurements were performed using the Quantity One 4.5 
tool (Bio-Rad). 
 
3.6 Colony formation assay in soft agar.  
The colony formation assay was performed to analyze anchorage-independent 
cell growth. Two hundred thousand cells were plated in 0.35% agar on a 
bottom layer of 1% agar in the 35-mm dishes of 6-well plates (Corning). The 
plates were incubated at 37 °C for 4 weeks, and then stained with 0.01% 
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crystal violet. Colonies with 20 cells or more were counted. The means and 
standard deviations were calculated from three independent experiments. 
 
3.7 Cell cycle distributions. 
 Cells were seeded in cell culture 10-mm × 20-mm dishes (Corning) at a 
density of 1 × 106 cells. After 8 h of serum starvation, the cells were treated 
with 5 μM and 10 μM ATRA for 24 h and 48 h. For the cell cycle analysis, 1 × 
106 cells were washed in PBS and resuspended in 20 μl propidium iodide (50 
μg/ml in PBS; Sigma), plus 50 μl RNaseA solution (100 μ g/ml in water; Sigma) 
and 0/004% NP40 in PBS. The cells were incubated at 37 °C for 3h in the dark. 
The cell-cycle distribution was then analyzed using flow cytometry, by 
fluorescence-activated cell sorting analysis (BD FACS, Canto II, BD 
Biosciences). The means and standard deviations were calculated from two 
independent experiments. 
 
3.8 Caspase-3 activity assay.  
Caspase-3 activity was evaluated using Caspase Fluorescent (AFC) 
Substrate/ Inhibitor QuantiPak (ENZO Life Sciences), following the 
manufacturer protocol. Briefly, cell lysates (total protein, 100 μg) were added 
to reaction mixtures (final volume, 100 μl) containing fluorigenic substrate 
peptides that are specific for caspase 3 (DEVD-AFC). The reaction was 
performed at 37 °C for 1 h. Fluorescence was measured with a fluorescence 
microplate reader (Microplate Imaging System, Bio-Rad), at 530 nm. 
 
3.9 Cell viability assay. 
 Cells were grown in the presence of ATRA for a total of 6 days. After 2 days, 
the cells were seeded as six replicates into 96-well plates at a density of 104 
cells per well. After 3, 4, 5, and 6 days of treatment, the metabolic activities of 
the samples were assessed as a surrogate marker for cell proliferation, using 
the 3-(4,5-dimethylthiazol-2l),5-diphenyltetrazolium bromide assay, according 
to the manufacture protocol (Promega). 
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3.10 Quantification of neurite outgrowth.  
Neurite outgrowth was defined as neurite processes that were equal to or 
greater than two times the length of the cell body [61]. Neurites as single, 
dispersed cells were measured from the cell body to the furthest tip of the 
process using the LeicaApplicationSuite/AF software and a DMI4000B 
microscope (Leica Mycrosystem). The means and standard deviations of the 
neurite populations were calculated from three independent experiments. 
 
3.11 Real-time RT-PCR.  
The expression levels of genes were analyzed using real-time, quantitative 
PCR. Total RNA extraction using TRIzol LS Reagent (Invitrogen) and cDNA 
retrotranscription using the High Capacity cDNA Reverse Transcription Script 
(Applied Biosistem) was performed according to the manufacturer protocol. 
The cDNA samples were diluted to 20 ng/μ l. Gene-specific primers were 
designed by using PRIMEREXPRESS software (Applied Biosystems). 
 
Real-time PCR was performed using SYBR Green PCR Master Mix 
(AppliedBiosystems). All real-time PCR reactions were performed using the 
7900HT Fast Real-Time PCR System (Applied Biosystems). The experiments 
were carried out in triplicate for each data point. The housekeeping gene β -
actin was used as the internal control. Relative gene expression was 
calculated using the 2−ΔCT method [62], where the ΔCT was calculated using 
the differences in the mean CT between the selected genes and the internal 
control (β -actin). The mean fold change of 2−(average ΔΔCT) was determined 
using the mean difference in the ΔCT between the gene of interest and the 
internal control. 
 
GENE PRIMER FORWARD PRIMER REVERSE
HIF1A CCCATAGGAAGCACTAGACAAAGT TGACCATATCACTATCCACATAAA
EPAS1 GACCCAAGATGGCGACATG TGTCCTGTTAGCTCCACCTGTG
TUJ-1 TATGAGGGAGATCGTGCACATC TGACTTCCCAGAACTTGGCC
MAP-2 TCTCTTCTTCAGCGCACCGGCG GGGTAGTGGGTGTTGAGGTACC
NEFL AAGCATAACCAGTGGCTACTCCCA TCCTTGGCAGCTTCTTCCTCTTCA
GFAP GGTTGAGAGGGACAATCTGGC GCTTCCAGCCTCAGGTTGG
S100 GCTGAAAGAGCTGCTGCAGA TTCATACACCTTGTCCACAGCAT
β-Actin CGTGCTGCTGACCGAGG GAAGGTCTCAAACATGATCTGGGT
NAV2 ACTTGGCCTCTATACCCGTC GAGGTATTTCGTTGCAGGGTCT
CDH7 GGACTGTCAGGAACTACATCAGTCA ATAAGACCTTCGAGGAAAGCGA 
PCDH17 GGGAGGCACTCAAGATGAAAACTA CTGTGCAATTAACACACTCTTCTGG 
DACH1  TTCCATCTCCTTTTCTGTTTCCTG  CAACTTTCAACAGCCCCTGTATG
SH3RF3 CAACGTGTACCTGGCGCTCTA ACCCGGTACATCTCTCCCTTG 
SPON1 GGCTCTCTGACCAAGAAACTTTGT  GGCACAGCAGTCTAAGATGGGT 
LAMA4 ACCGGAGAATGCTTGGAAGAA CCAGACGCACTTATCACAGCTTAT 
TMEM45A AACCATTGTCATCGTTGGAATG TCTGAGGAGCAGAGCCTCTTAAGT 
PARP4 TGTGGTGCCGGAGTATTTGAA CCTGGTCATTTGGTCTTCTATCTGT
GABRB3 TCTGGAAATTGAAAGCTATGGCTAC ACTCCGGTAACAGCCTTGTCC
SLC35F3 AGTCCACAGAGAAGCAGTCTGTGA CCTTCAAAGTCAAGCCATTGTCT
KIF26B CGATGCAGTTTTTCCACAAGAC GTTGACCACAGACTGGATCACCT
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3.12 Immunofluorescence.  
Cells were placed on the chambers of polystyrene vessel tissue culture treated 
glass slides (BD Falcon), fixed in 4% paraformaldehyde, permeated with 0.2% 
Triton X-100, and blocked with 1% bovine serum albumin. The anti-GFAP 
(SAB4100002, Sigma) primary antibody was incubated for 1 h to 3 h, and the 
AlexaFluor 546 donkey anti-mouse (A10036, Invitrogen) secondary antibody 
for 45 min. Nuclear staining was obtained using 4’,6-diamino-2-phenylindole 
(DAPI, Roche) (1:10,000 dilution in methanol). Confocal microscopy images of 
cells were acquired using a point-scanning confocal microscope (Zeiss LSM 
510 Meta; Zeiss, Germany) with a 40 × EC Plan-Neofluar oil-immersion 
objective. Digital images were acquired using the LSM 510 Meta software60. 
All of the instrumental parameters for the fluorescence detection and image 
analyses were held constant to allow cross-sample comparisons. 
 
3.13 Senescence analysis.  
Senescence of cells during differentiation experiments was analyzed using 
Senescence β -Galactosidase Staining kits (Cell Signaling Technology). 
Briefly, the cells were fixed in 2% glutaraldehyde/ 20% formaldehyde and then 
stained at 37 °C overnight with the X-gal staining solution. The blue cells were 
considered positive. The means and standard deviations were calculated from 
three independent experiments. 
 
3.14 RNA-sequencing. 
Total RNA was isolated from NB cell line using TRIzol LS Reagent (Invitrogen) 
according to manufacturer’s instructions, samples quality is assessed with 
Agilent 2100 Bioanalyzer RNA Nano chip device (Agilent, Santa Clara, CA, 
USA), and total RNA concentrations were determined using a NanoDrop ND-
1000 spectrophotometer (Nano-Drop, Wilmington, DE, USA). RNA with an 
OD260/280 between 1.8 and 2.2 and an OD260/230 ≥ 1.8 was used for the 
construction of cDNA libraries.  
 
3.15  cDNA library construction and sequencing. 
The mRNA content was concentrated from total RNA using RNase-free DNase 
I (TaKaRa) and magnetic oligo (dT) beads. The mRNA was mixed with the 
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fragmentation buffer and broken into short fragments (~200 bp long). Then, 
the first strand of cDNA was synthesized with a random hexamer primer. The 
second strand was synthesized using the SuperScript Double-Stranded cDNA 
Synthesis kit (Invitrogen, Camarillo, CA) and was purified via magnetic beads. 
The ends were repaired and tailed with a single 3’ adenosine. Subsequently, 
the cDNA fragments were ligated to sequencing adapters. Sequencing was 
accomplished using an Illumina HiSeq™ 2000 platform according to the 
manufacturer’s protocols (Analysis performed by BIOGEM facillity). 
 
3.16 RNA-seq data analysis  
The analysis started from cleaned data previously filtred by adapter 
sequencies, low quality reads and from reads with more than 10% of unknown 
bases. Quality assessment on cleaned FASTQ files was performed using 
FastQC [63]. Sequencing data were analysed with the set of open source 
software programs of the Tuxedo suite: TopHat v2.0.14 and Cufflinks, 
following the analysis pipeline pubblished in nature protocol 2012.TopHat is a 
fast splice junction mapper for RNA-Seq reads. It aligns RNA-Seq reads to the 
reference genome using the ultra high-throughput short read aligner Bowtie2 
v2.2.6.0, and then analyzes the mapping results to identify splice junctions 
between exons. TopHat was ran with default options by providing the 
reference genome (assembly GRCh37/hg19 downloaded from UCSC and 
indexed with Bowtie2) and its related RefSeq reference transcriptome 
(downloaded from UCSC) along with the couple of FASTQ files (forward and 
reverse reads) for each sample. Next, Cufflinks was used to assemble the 
mapped reads (in the BAM file format) into possible transcripts and to generate 
a final transcriptome assembly. The tool Cuffmerge was exploited to merge 
transcriptomes from all samples and generate a common transcriptome file. 
Cuffdiff was finally used to detect differentially expressed genes and 
transcripts. It takes mapped reads from two or more biological conditions 
(provided as two or more biological replicates) and analyzes their differential 
expression of genes and transcripts, thus aiding in the investigation of their 
transcriptional and post transcriptional regulation under different conditions. 
The program was ran by providing all the obtained BAM files (specifying the 
experimental condition and the replicate to which they belonged), the merged 
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transcriptome assembly and the sequence of the reference genome. The 
software returned: FPKM counts (Fragments Per Kilobase Of Exon Per Million 
Fragments Mapped) for each replicate, averaged FPKM counts for each 
experimental condition, and pairwise comparisons from the different 
experimental conditions (reporting the differences in expression levels). The 
set of output files obtained by Cuffdiff, reporting was then inspected and 
explored using the R-Bioconductor package CummeRbund v2.16.0, which 
provides functions to read, subset, filter and plot results. 
 
3.17 RNA-seq Differential expression analysis 
Genes were considered as differentially expressed in each of the pairwise 
comparisons if the comparison Bonferroni adjusted P-value was under 0.05 
and if the fold change was greater than +0,5 (overexp) or lower than -0,5 
(underexp). The lists of these genes were used to query Pathway and Gene 
Ontology databases. 
 
3.18 Statistical analysis. The differences between the groups were analyzed 
using unpaired student’s t-test. Probability values <0.05 were considered to be 
statistically significant. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001. 
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4. RESULTS 
 
4.1 Association of HIF1A and EPAS1 expression with clinical outcomes 
in patients with NB. 
In NB cell lines, hypoxia-regulated pathways and/or HIF expression have been 
shown to promote an undifferentiated phenotype, either through 
dedifferentiation or through inhibition of differentiation. So it can be considered 
that HIF1A and EPAS1 overexpression in patients with high-risk NB will 
contribute to differentiation therapy resistance and to tumor cell 
aggressiveness. Firtsly was evaluated the association of HIF1A and EPAS1 
expression with clinical outcomes in NB patients using two datasets that are 
deposited in the R2 microarray web tool: the Seeger dataset that included 102 
patients; and the Versteeg dataset that included 88 patients. The Seeger 
dataset includes patients with high-risk NB (i.e., stage 4 disease), whereas the 
Versteeg dataset includes patients with different stages and ages at diagnosis. 
As shown in figure 4.1.1, high mRNA levels of HIF1A were significantly 
associated with lower overall survival and relapse-free survival in both sets of 
patients, whereas high expression levels of EPAS1 showed significant 
association with lower overall survival and a trend toward an association with 
lower relapse-free survival, although this did not reach statistical significance. 
 
 
Figure 4.1.1. HIF1A and EPAS1 gene expression is associated with poor survival in patients with NB. 
Kaplan-Maier analysis with patients grouped by the optimal cut-off (calculated using the R2 web tool) of expression 
of HIF1A and EPAS1 for overall survival and relapse-free survival rates, in 88 patients with NB (Versteeg dataset) 
and 102 International Neuroblastoma Staging System stage 4 patients with MYCN not amplified (Seeger dataset). 
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The overall survival data of the Seeger dataset were not available. The “raw P” indicates the uncorrected p-value, 
whereas the “bonf P” indicates the p-value corrected for multiple tests according the Bonferroni method. 
 
In both of these datasets, two patient subgroups were identified with different 
expression levels of HIF1A and EPAS1, in terms of their ‘High’ and ‘Low’ 
expression levels. So it was investigated whether, the different expression of 
these genes, between the two subgroups can influence the neuronal 
differentiation pathways. 
Genes differentially expressed between ‘High’ and ‘Low’ HIF1A or EPAS1 
(mRNA expression levels), were filtred selecting only which included in the 
category “Development”and submitted for gene ontology analysis. As shown 
in figure. 4.1.2, the neuronal differentiation pathways were more represented 
in the patient group for ‘Low’ HIF1A or EPAS1 expression than for ‘High’ HIF1A 
or EPAS1 expression (P ≤ 0.05).  
 
 
 
Figure 4.1.2. Pathway analysis of the genes involved in development that were differentially expressed 
between patients with ‘High’ and ‘Low’ levels of HIF1A and EPAS1 expression. Results of the pathway analysis 
for the genes involved in development in patients with ‘High’ and ‘Low’ mRNA levels of HIF1A andEPAS1 (P ≤ 0.05). 
 
Furthermore MAPK PI3K-AKT signaling pathways were represented in the 
‘High’ and ‘Low’ EPAS1 expression subgroups in both datasets [64]. 
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Interestingly, the IL-1B, IKBKB, RELA and NFKB1 genes were more 
expressed in the ‘High’ (HIF1A and EPAS1) expression subgroups in the 
Versteeg dataset, while the same factors were overexpressed only in the ‘High’ 
HIF1A expression subgroup in the Seeger dataset (Figure 4.1.3) 
 
 
Figure 4.1.3. IKBKB, RELA, NFKB1 and ILB1 expression in the subgroups of patient with NB. Box plots showing 
the expression levels (Log2) of IKBKB, RELA, NFKB1 and ILB1 in the patient subgroups of ‘Low’ HIF1A and ‘High’ 
HIF1A expression in the Versteeg (A) and Seeger (C) datasets, and in the ‘Low’ EPAS1 and ‘High’ EPAS1 expression 
in the Versteeg (B) and Seeger (D) datasets.  
 
4.2 HIF1A and EPAS1 silencing in NB cells 
For the next experiments three NB cell lines were selected: SHSY5Y, 
SKNBE2c and SKNAS cells. The SHSY5Y and SKNBE2c cell lines have 
biochemical features of neuronal cells, and these are believed to represent 
embryonic precursors of sympathetic neurons. These cells differentiate toward 
a neuronal phenotype upon RA treatment. The SKNAS cells have the flat 
phenotype of glial cells, and they do not differentiate [58,59]. These three cell 
lines showed different basal levels of HIF1A and EPAS1 expression, as shown 
by their 2^−ΔCT values, which represent their relative gene expression.  
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The SHSY5Y and SKNAS cells had higher levels of HIF1A expression than 
the SKNBE2c cells. EPAS1 expression was higher in the SHSY5Y cells with 
respect to the SKNBE2c and SKNAS cells. The SKNBE2c cells showed the 
lowest levels of both HIF1A and EPAS1 expression, with respect to the 
SHSY5Y and SKNAS cells (Figure 4.2.1 A). In the same cells grown under 
hypoxic conditions, these HIF1A and EPAS1 relative mRNA levels (2^−ΔCT) 
were decreased with respect to those in the cells grown under normoxic 
conditions (Figure 4.2.1 A, HYP, NX, respectively). As shown by the Western 
blotting in (Figure 4.2.1 B), the expression levels of the HIF-1α and HIF-2α 
proteins (as determined by the integral optical densities [IODs], and 
normalized with respect to lamin-β expression) were stabilized in these NB 
cells grown under hypoxic conditions. HIF-1α protein expression was more 
stabilized than HIF-2α protein expression. These data suggest that the HIF1A 
and EPAS1 mRNA levels decreased probably because the increases in the 
HIF-1α and HIF-2α protein levels would result in negative feedback on their 
mRNA production 
 
 
Figure 4.2.1. HIF1A and EPAS1 and HIF-1α and HIF-2α protein expression under normoxia and hypoxia 
conditions. The three cell lines (SHSY5Y, SKNBE2c, SKNAS) were grown in normoxia (NX) and hypoxia (HYP) (1% 
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oxygen for 6 h). The relative mRNA expression of HIF1A and EPAS1 normalized to β –actin expression as determined 
(2−ΔCT) from the RT-PCR analysis (A). Western blotting of nuclear extract from the cells grown under normoxia (N) 
and hypoxia (H) conditions shows HIF-1α and HIF-2α changes under hypoxia. The bands were quantified by 
densitometry. The bar graphs shows the integral optical density (IOD) for each band, normalized with respect to lamin-
β expression (B). Data are means of three experiments. 
 
The HIF1A and EPAS1 silencing in these NB cell lines under normoxic 
conditions was mediated using lentiviral delivery of short hairpin (sh)RNAs 
directed against HIF1A and EPAS1 (i.e., shHIF1A and shEPAS1, 
respectively). A non-silencing shRNA was delivered using the lentivirus in the 
control cells (shCTR). The efficiency of silencing was determined by RNA 
expression (RT-PCR), as shown in (Figure 4.2.2 A), where the gene 
expression is given as percentages relative to the shCTR cells (at 100%). In 
the gene silencing here, HIF1A mRNA expression was significantly decreased 
in the SHSY5Y (by 33.8% ± 1.9%), SKNBE2c (by 42% ± 5.1%) and SKNAS 
(by 28% ± 1.3%) shHIF1A cells. EPAS1 mRNA expression was also 
significantly decreased in the SHSY5Y (40% ± 4.8%), SKNBE2c (48% ± 
12.0%) and SKNAS (46% ± 4.1%) shEPAS1 cells. These decreases in HIF1A 
and EPAS1 mRNA were enough to influence the transcription of the target 
genes downstream of HIF, as shown in the appendices (Figure 7.1). The 
efficiency of the silencing was also determined by Western blotting in these 
three cell lines. As shown in Figure 4.2.2 B there were decreases in the HIF-
1α and HIF-2α protein levels upon HIF1A and EPAS1 mRNA silencing, 
respectively. The decrement of HIF1A and EPAS1 gene expressions were 
sufficient to reduce the oncogenic potential of NB cells, as shown by soft agar 
assays. Figure 4.2.2 C shows that there were decreases in the colony 
formation numbers in the SHSY5Y shHIF1A (54 ± 7.7 colonies) and shEPAS1 
(52.5 ± 9.2 colonies) cells compared to the SHSY5Y shCTR cells (84 ± 4 
colonies). Similarly for the SKNBE2c shHIF1A (45 ± 8.4 colonies) and 
shEPAS1 (38.5 ± 0.7 colonies) cells compared to the SKNBE2c shCTR cells 
(71 ± 2.8 colonies). The SKNAS cells showed weaker growth than the SHSY5Y 
and SKNBE2c cells, and HIF1A/EPAS1 mRNA depletion did not affect their 
growth (data not shown). 
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Figure 4.2.2. HIF1A and EPAS1 silencing in NB cells and the effects on cell growth in the colony formation 
assay. (A) Efficiency of gene silencing mediated by lentiviral delivery of hairpin RNAs directed against HIF1A and 
EPAS1 (shHIF1A, shEPAS1, respectively) in the three NB cell lines (SHSY5Y, SKNBE2c, SKNAS) was assessed 
using RT-PCR. Data are means of three experiments and are represented as percentages with respect to the NB 
shCTR cells, which were infected by lentivirus-mediated delivery of non-silencing hairpin RNA. (B) Western blotting 
of nuclear extracts from HIF1A and EPAS1 silenced cells showing the decreases in the HIF-1α and HIF-2α proteins. 
The bands were quantified by densitometry. The bar graphs show the integral optical density (IOD) for each band, 
normalized with respect to lamin-β expression. (C) HIF1A and EPAS1 silencing in SHSY5Y and SKNBE2c cells affects 
cell growth in the soft agar colony formation assay. The graft bars show decreased colony numbers in the NB 
shHIF1A/shEPAS1 cells compared to the NB shCTR cells. The SKNAS cells are not shown (** P ≤ 0.01; *** P ≤ 
0.001). 
 
4.3 Combination of ATRA with HIF1A or EPAS1 silencing enhances the 
Schwann cell-like phenotype. 
The initial purpose was to determine the effects of HIF1A and EPAS1 silencing 
on cell differentiation induced by ATRA in NB cells: SHSY5Y and SKNBE2c 
RA responsive and SKNAS RA unresponsive. These cell lines were silenced 
for HIF1A or EPAS1 expression and then treated for 6 days with 5 μM and 10 
μM ATRA. As reported in the literature, these ATRA concentrations can induce 
differentiation in diverse NB cells without any toxicity resulting from such 
prolonged treatments [58,59,64,65]. 
It is known that ATRA treatment increases the expression of HIF-1α in acute 
promyelocitic leukemia and in other cell types [29], and more remarkably, that 
HIF-1α inhibition cooperates with ATRA in the reduction of APL disease [66]. 
Here, we investigated the levels of the HIF-1α and HIF-2α proteins in these 
ATRA-treated NB cells. ATRA treatment alone induced increases in the HIF-
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1α protein levels, as expected, and HIF1A silencing combined with ATRA 
treatment prevented this ATRA-induced HIF-1α increase (Figure 4.3.1). No 
increases in the HIF-2α protein were observed here. According to these data, 
inhibition of HIF in ATRA-treated tumors might synergize with ATRA, and so 
improve the success of this therapy. 
 
 
 
Figure 4.3.1. HIF-1α and HIF-2α protein expression upon ATRA treatment. SHSY5Y, SKNBE2c and SKNAS 
shCTR, shHIF1A, and shEPAS1 cells were treated with 5 µM or 10 µM ATRA or vehicle (V) for 6 days. (A) Western 
blotting shows HIF-1α protein levels (A) and HIF-2α protein levels upon ATRA treatment. Bar graphs show the integral 
optical density (IOD) for each band normalized respect to lamin-β expression. The IOD are expressed in percentages 
with respect to vehicle treated cells. 
 
 
ATRA can induce differentiation in numerous NB cell lines, which forces the 
cells out of the cell cycle. We examined the proportions of SHSY5Y, SKNBE2c 
and SKNAS cells at each stage of the cell cycle, through their caspase 
activities and their cell proliferation upon ATRA treatment and HIF1A or EPAS1 
silencing. Flow cytometry revealed that in the SHSY5Y shCTR, shHIF1A, and 
shEPAS1 cells and in the SKNBE2c shCTR, shHIF1A, and shEPAS1 cells, 
ATRA generated a modest accumulation of cells in G0/ G1, with depletion of 
the cells in the S-phase and the G2 phase (Figure 4.3.2 A and appendices 
7.2). This depletion in the S-phase in response to ATRA treatment also showed 
increased caspase activities and reduced cell proliferation rates (Figure 4.3.2 
B-C). Interestingly, the caspase activities in the SHSY5Y and SKNBE2c cells 
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were similarly increased with ATRA treatment for the SHSY5Y and SKNBE2c 
shCTR, shHIF1A and shEPAS1 cells, which suggested that this co-treatment 
does not promote any increase in apoptosis. The absence of G1 accumulation 
and any increase in caspase activity, as well as the unvaried rate of 
proliferation in the treated SKNAS shCTR, shHIF1A, shEPAS1 cells indicated 
the failure of ATRA-induced cell differentiation in these cells. 
 
 
 
Figure 4.3.1. ATRA treatment: cell cycle and caspase activity. (A) Cells silenced for HIF1A or EPAS1 expression 
were treated for 6 days with 5 µM or 10 µMATRA and processed for flow cytometry using propidium iodide. The 
proportion of cells at each stage of the cell cycle were calculated. (B) Caspase-3 activity was assessed in the same 
cells (V, vehicle; 5 µM and 10 µMATRA), and the data were normalized with respect to the negative control. (C) Cell 
viability was measured using the MTT assay, after 3, 4, 5, and 6 days (D) of ATRA treatment. Significances between 
the vehicle and the ATRA-treated cells are shown. The data are means of two experiments (* P < 0.05). 
 
To estimate the neuronal differentiation under these treatments, a phenotype 
analysis was carried out, where the number of neuronal and flat cells were 
counted [67]. These data are expressed as percentages (Figure. 4.4.1A). In 
the SHSY5Y shCTR cells, with the 5µM and 10 µM ATRA treatments, there 
were more neuronal cells (75% ± 5%; 85% ± 5%; respectively) than flat cells 
(25% ± 5%; 16.6% ± 5.5%; respectively) (Figure. 4.1.1B). In contrast, upon 10 
µM ATRA treatment in the SHSY5Y shHIF1 A and shEPAS1 cells, there were 
significant increases in the numbers of flat cells that were paralleled by 
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decreases in the neuronal cells, compared to the SHSY5Y shCTR cells 
(Figure. 4.4.1B; P ≤ 0.05). In particular, in the SHSY5Y shHIF1 A cells, there 
were 49% ± 6.3% neuronal cells and 51% ± 7.0% flat cells, and in the SHSY5Y 
shEPAS1 cells there were 55% ± 1.5% neuronal cells and 37% ± 7.5% flat 
cells (Figure. 4.4.1B). These decreases in the neuronal-like cells at 5 µM and 
10 µM ATRA treatment were accompanied by shorter mean neurite lengths in 
the SHSY5Y shHIF1A cells (38 ± 0.4 µm; 49 ± 13.0 µm) and the SHSY5Y 
shEPAS1 cells (44 ± 3.0 μm; 48 ± 10.8 μm), compared to the SHSY5Y shCTR 
cells (65 ± 16.0 µm; 63 ± 17.3 µm), (P ≤ 0.05) (Figure. 4.4.1C). In the SKNBE2c 
shCTR cells, there were increased numbers of neuronal cells with 5 µM ATRA 
(68% ± 3.8%) and 10 µM ATRA (73% ± 13.0%) treatment, with respect to the 
flat cells with 5 µM ATRA (32% ± 5.4%) and 10 µM ATRA (27% ± 4.3%) 
treatment. In the SKNBE2c shHIF1A and shEPAS1 cells, instead, there were 
significantly increased numbers of flat cells with respect to a decrease in the 
number of neuronal cells, when compared to the SKNBE2c shCTR cells (P ≤ 
0.005). In particular, for the SKNBE2c shHIF1A cells, upon 5 µM ATRA 
treatment there were 19% ± 3.7% neuronal cells and 81% ± 2.7% flat cells, 
and upon 10 µM ATRA treatment there were 26% ± 5.3% neuronal cells and 
73% ± 0.1% flat cells. For the SKNBE2c shEPAS1 cells, upon 5 µM ATRA 
treatment there were 33% ± 3.2% neuronal cells and 68% ± 10.0% flat cells, 
and upon 10 µM ATRA treatment there were 32% ± 5.0% neuronal cells and 
68% ± 20.0% flat cells. The neuronal cell population did not show substantial 
differences in mean neurite length (Figure. 4.4.1B-C) The SKNAS shCTR, 
shHIF1A, and shEPAS1 cells did not show an obvious phenotypic responses 
to ATRA (Figure. 4.4.1A). 
 
4.4 Combination of ATRA with HIF1A or EPAS1 silencing affects 
neuronal marker expression in NB cells 
To determine the neuronal differentiation, NB shCTR, shHIF1A and shEPAS1 
cells were treated these for 6 days with 10 µM ATRA and multiple factors that 
are known to be involved in axon guidance were investigated: beta-III-tubulin 
(TUJ-1) and microtubule-associated protein 2 (MAP-2), which are involved in 
microtubule assembly; neuronal light intermediate filament (NEFL), which is 
expressed during neuronal differentiation; glial fibrillary acidic protein (GFAP), 
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which is expressed by astrocytes, and S100, which is expressed in cells 
derived from the neural crest (Schwann cells, melanocytes), both of which are 
implicated in the dynamics of cytoskeleton constituents. As determined by RT-
PCR, after 10 µM ATRA treatment, in the SHSY5Y shCTR cells there was 
increased expression of the neuronal markers that was not seen in the 
SHSY5Y shHIF1A and shEPAS1 cells (except for MAP-2, the expression of 
which increased in the treated SHSY5Y shHIF1A cells) (Figure 4.4.1 D). 
Furthermore, all of these three SHSY5Y cells did not express glial markers at 
that time of treatment (data not shown). In the SKNBE2c shCTR cells, there 
were increases in neuronal marker expression, and in the SKNBE2c shHIF1A 
and shEPAS1 cells there were increases in glial marker expression. Although 
HIF1A or EPAS1 silencing appeared to enhance the ATRA-induced glial 
marker expression, the glial markers were more highly expressed in the 
SKNBE2c shHIF1A cells than the SKNBE2c shEPAS1 cells. There were no 
differences in the expression of the neuronal and glial markers between the 
SKNAS shCTR, shHIF1A, and shEPAS1 cells (except for TUJ-1, the 
expression of which decreased in the ATRA-treated SKNAS shCTR cells 
compared to the ATRA-treated SKNAS shHIF1A and shEPAS1 cells). 
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Figure 4.4.1. ATRA treatment combined with HIF1A or EPAS1 silencing enhances the glial phenotype. (A, B) 
SHSY5Y, SKNBE2c, and SKNAS cells were silenced for HIF1A or EPAS1 expression (shHIF1A, shEPAS1, 
respectively) and treated with 5 µM (not shown) and 10 µMATRA, or only with vehicle (V), for 6 days. Phenotypic 
changes were analyzed by counting the cells that showed the neuronal and flat-cell phenotypes, in six different fields 
for each experimental point. The data are expressed as percentages. Blue arrows, examples of neuronal cells; yellow 
arrows, examples of flat cells. (C) The mean neurite lengths of the counted cells (µm). (D) Gene expression analysis 
of TUJ-1, NEFL, GFAP and S100 performed using RT-PCR in the three NB cell lines. Data are means of three 
experiments (* P ≤ 0.05; ** P ≤ 0.01). 
 
To determine whether this co-treatment might be more long-lived, cells were 
treated the with 10 µM ATRA for 25 days, and then it was assessed their 
differentiation status (Figure 4.5.1 A). Upon this extended 10 µM ATRA 
treatment, GFAP immunostaining was observed in the SHSY5Y and SKNBE2c 
shHIF1A and shEPAS1 cells, but not in vehicle-treated cells (Figure 4.5.1 A 
V). In the ATRA-treated SHSY5Y and SKNBE2c shCTR cells, GFAP 
expression was very weak in the cytoplasm. The immunostaining of the glial 
marker GFAP in both of these cell lines supports the phenotypic changes in 
these SHSY5Y and SKNBE2c shHIF1A and shEPAS1 cells. As shown in 
figure 4.5.1 B, the SHSY5Y shCTR cells preserved a neuronal-like phenotype, 
whereas the SHSY5Y shHIF1A and shEPAS1 cells gained a highly fusiform 
phenotype and formed pseudoganglia, which are typical of primary neurons. 
In the SKNBE2c shCTR cells, there was a mixed population of thread-like and 
flat cells, while the SKNBE2c shHIF1A and shEPAS1 cells showed glial 
phenotypes. 
 
4.5 Combination of ATRA with HIF1A or EPAS1 silencing results in 
senescence of NB cells 
NB shCTR, shHIF1A, and shEPAS1 cells were also treated with 5 µM and 10 
µM ATRA for 40 days, and then analyzed them for their senescence state. 
These final cell populations were tested for senescence-associated β-
galactosidase (Figure 4.5.1 C) [68]. Vehicle-treated NB shHIF1A and 
shEPAS1 cells showed greater senescence compared to the vehicle-treated 
NB shCTR cells (Figure 4.5.1 D; except for the SHSY5Y shEPAS1 cells). This 
suggested that the decreased HIF1A and EPAS1 expression in these NB cells 
might make them more prone to go into senescence, independent of the ATRA 
treatment. Furthermore, the combination of the ATRA treatment with the 
HIF1A or EPAS1 gene silencing showed greater senescence in the SHSY5Y 
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(10 µM ATRA) and SKNBE2c (5 μM, 10 μM ATRA) cells, but not in the SKNAS 
cells (Figure 4.5.1 C-D). 
 
 
Figure 4.5.1. Long-term combination treatment of the NB cell lines. (A) After 25 days of ATRA treatment, HIF1A 
or EPAS1 silenced and ATRA-treated SHSY5Y and SKNBE2c cells were immunostained with an antibody against 
GFAP. The settings of the confocal microscope were strictly maintained throughout the whole study. The panels are 
representative of three independent experiments. (B) SHSY5Y and SKNBE2c shCTR cells show thread-like structures 
that indicate neuronal differentiation; whereas the SHSY5Y and SKNBE2c shHIF1A cells grow similar to ganglion 
structures, and the SHSY5Y and SKNBE2c shEPAS1 cells show a mixed population of flat and neuronal cells. The 
SKNAS cells did not show any morphological change. (C, D) After 40 days of treatment, the cells showed 
morphological evidence of senescence, which included the expression of senescence-associated-β -galactosidase 
(SA-β -Gal). Quantification was performed for the percentages of enlarged cells that showed SA-β -Gal expression. 
Data are means of three experiments (*P ≤ 0.05). 
 
4.6 HIF1A affects chromatin state and gene expression regardless 
microenviroment. 
To asses wheter HIF1A may affect chromatin state, SKNBE2c cell lines shCTR 
and shHIF1A grown normoxia (NX) and hypoxia (HYP) condition were 
analysed evaluating their nuclei dimension, using LeicaApplicationSuite/AF 
software and a DMI4000B microscope (Leica Mycrosystem). Larger nuclei in 
hypoxia are indicative of chromatin decondensation [86].  Dapi staining in 
figure 4.6.1 shows a significative increase of nuclei size (represented in 
histogram) in HIF1A silenced cells compared to CTR cells grown in NX, while 
nuclei size in HYP do not seems to vary after HIF1A depletion. Moreover, 
35 
 
nuclei size are greater in cells grown in HYP compared to NX grown cells. 
These findings underline, as expected, that hypoxia and its related factors 
affect chromatin state, further suggesting that HIF1A is able to interfere with 
chromatin structure in an oxygen independent way. 
 
 
Figure 4.6.1 Nuclei dimentions in HIF1A silenced NB cell line in normoxia and hypoxia conditions. Dapi staining 
of HIF1A silencend SKNBE2c cells grown in hypoxia and normoxia conditions. Histograms show nuclei dimention in 
µM assesed with LeicaApplicationSuite/AF software and a DMI4000B microscope Leica Mycrosystem. 
 
To provide genes and pathways differentially regulated by HIF1A, silenced 
SKNBE2c NB cell lines grown in NX and HYP (0,1 % O2) conditions were 
subjected to RNA-seq esperiment. SKNBE2c cells have showed phenotypic 
and developmental intermediate features, (derived from their neural crest 
precursors) during retinoids treatments and this aspect makes them the best 
choise for our further studies, because best representing the eterogeneity of 
the tumor. Four experimental samples SKNBE2c shCTR NX, shCTR HYP, 
shHIF1A NX and shHIF1A HYP, each one in triplicates, were tried for RNA 
seq. For each samples RNA was prepared for the sequencing with HiSeq 2500 
(illumina) as follows: purification, fragmentation, cDNA synthesis and libraries 
design (Biogem facility). Row data resulting from the sequencing were 
analysed with the set of open source software programs TopHat v2.0.14 and 
Cufflinks (Tuxedo) following the analysis pipeline (Nature protocol 2012). This 
data sets, allowed to generate “two gene sets”, that represents differential 
expression genes from shHIF1A HYP compared to shCTR HYP and shHIF1A 
NX compared to shCTR NX. RNA-seq data of differentialy expressed genes, 
were sorted by the measure of log2 fold change (≥+0,5 or ≤-0,5). The log2 fold 
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change represents the value of different expression between shHIF1A genes 
versus shCTR genes (Figure 4.6.2).  
The reliability of RNA-seq data was assesed by RT-PCR. Twelve genes were 
chosen from the comparison shHIF1A HYP vs shCTR HYP (Appendices 7.3) 
with value of log2 fold change ≤+2 and ≥ -2. 
 
 
 
Figure 4.6.2 RNA-seq experiment. Overview of SKNBE2c shCTR and sh HIF1A grown in normoxia (NX) and 
hypoxia (HYP) condition. RNA-seq experiment (design, making libraries, sequencing, data analysis).  
 
From the analysis of these “two gene sets” 2261 genes were found 
differentially regulated in the comparison shHIF1A sh NX vs shCTR NX and 
1839 genes comparing shHIF1A HYP vs shCTR HYP. As observed in figure 
4.6.3, gene ontology analysis of “two gene sets” (using the WEB-based GEne 
SeT AnaLysis Toolkit web tool-webGestalt) shows that HIF1A regulates the 
same pathways in both oxygen conditions; with the difference that there is an 
increase of metabolic activity in normoxia and of axon guidance pathway in 
hypoxia. HIF1A in normoxia is able to affect the expression of much more 
genes (2261) rather than in hypoxia conditions (1893), anyway the 
distribution’s percentage of up and downregulated genes has the same trend 
between the different O2 levels.  
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Figure 4.6.3: RNA-seq data processing(I). In red circle HIF1A target genes regulated in normoxia, in blue circle 
HIF1A target genes regulated in hypoxia. Histograms represent the percentage of genes up (log2 fold chage ≥0,5) 
and down (log2 fold chage ≤-0,5) regulated in two gene sets. The table shows the results of KEEG pathway analysis 
p-value ≤0,05 and ≥10 genes for pathway.  
 
The next step was to identify HIF1A target genes regulated in both O2 
conditions. To this aim the “two gene sets” (figure 4.6.4) (shHIF1A vs shCTR 
hypoxia and shHIF1A vs shCTR normoxia) were matched and three gene lists 
were obtained: 1) HIF1A target genes regulated “exclusively in hypoxia”,with 
637 genes, 2) HIF1A target genes regulated “exclusively in normoxia” with 
1405 genes and 3) a list of genes which are commonly regulated in hypoxia 
and normoxia with 1256 genes, named “HIF1A-target genes” (figure 4.4.5 A). 
To deeply investigate the function of HIF1A on gene regulation in normoxia 
and hypoxia, HIF1A target genes regulated “exclusively in normoxia” and 
“exclusively in hypoxia” were analyzed. As observed in figure 4.6.4 the number 
of HIF1A target genes regulated “exclusively in normoxia” are greather than 
the number of genes regylated “exclusively in hypoxia”. Furthermore, we 
observed a significative difference in gene numbers that are down and up 
regulated, in particular 72% NX vs 56 % HYP down regulated and 28% NX vs 
44% HYP upregulated. KEGG pathway analysis (webGestalt) of the two 
“excluxive” gene sets revealed an enrichment of metabolic and cellular energy 
intake pathways in normoxia opposed to an enrichment of axon guidance and 
cancer pathways in hypoxia. These results underline a different HIF1A role in 
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normal and in low oxygen level conditions. Infact seems reasonable to 
suppose a HIF1A role in metabolic process in both conditions, with a switch 
versus the regulation of neuron differentiation pathway when HIF1A is 
depleted. Thus, HIF1A has a role in metabolic pathways in hypoxia, which is 
less revelant than its role in neuronal differentiatiation. 
 
 
Figure 4.6.4: RNA-seq data processing(II) In red circle HIF1A target genes regulated “exclusively in normoxia, in 
blue circle HIF1A target genes regulated “exclusively in hypoxia. Histograms represent the percentage of genes up 
(log2 fold chage ≥0,5) and down (log2 fold chage ≤-0,5) regulated in two gene sets. Table shows KEEG pathway 
analysis p-value ≤0,05 and ≥10 genes for pathway. 
 
In figure 4.6.5 are shown “HIF1A-target genes” commonly regulated by 
absence of HIF1A in both hypoxia and normoxia conditions. The expression 
values of these genes (about -7,2 and +4,7 log2 fold change) are shown in 
figure 4.6.5 B. Interestingly, as obeserved in dotplot each gene has the same 
regulation trend (up and down) in both O2 conditions. This is not true for 19 
genes (less than 1,6 %). Gene ontology analysis of “HIF1A-target genes” has 
revealed an enrichment in pathway of MAPK signaling, axon guidance and 
cancer (webGestalt). Particulary the same MAPK signaling and axon guidance 
pathaways have been found to be altered in NB patients with low HIF1A 
expression levels (in mentioned two NB microarray datasets) in figure 4.6.5 C.  
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Figure 4.6.5: RNA-seq data processing(III). (A) In red circle HIF1A target genes regulated “exclusively in normoxia, 
in blue circle HIF1A target genes regulated “exclusively in hypoxia” and in yellow circle HIF1A target genes. (B) Dot 
plot shows regulation trend of HIF1A target genes (up≥0,5 and down≤-0,5), (C)table shows KEEG pathway analysis 
of HIF1A-target genes p-value ≤0,05and considerind ≥10 genes for pathway. 
 
Various genes are mutated at relatively low frequency in NB but with potential 
biological functions. In order to asses whether HIF1A targets might be mutated 
in high-risk NB (HR-NB), “HIF1A-target list” was crossed with a list of 
significantly mutated genes in NB tissues (with non-silent somatic changes), 
derived from WES and DT-seq of 17 matched germline and HR-NB tissue pairs 
[27] [Table 7.3] (Figure 4.6.6 A). 
The twelve genes resulting from this crossing were further filtred to find a 
proposable HIF1A target to use in cotreatment with RA. In particular the genes 
down-represented (negative value of log2 fold change) in absence of HIF1A 
(RNAseq data in SKNBE2c cells) were selected because the intent of this 
study is to propose HIF1A direct target to hit for improvement of NB therapies. 
These genes are: FGFR1 (Fibroblast Growth Factor Receptor 1) FZD1 
(Frizzled Class Receptor 1) and SYT13 (Synaptotagmin 13). Furthermore, the 
correlation of these gene expressions to NB patients survival was evaluated in 
two NB microarray datasets mentioned before (deposited in the R2 microarray 
web tool). As observed in Kaplan-Meier curve (Figure 4.6.6 B) FGFR1 and 
FDZ1 expression were associated with patients bad clinical outcome in both 
datasets. Contrary SYT13 expression is associate with good clinical outcame 
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(high relaps free survival) in Versteeg dataset and with bad clinical outcame 
(with no significative P-value) in Seeger dataset.  
 
 
 
Figure 4.6.6“HIF1A target genes” found to be mutated in NB tissues: (A)Comparison of HIF1A target genes 
obtained by RNA-seq, and gene list of mutated gene in NB tissues obtained by WES and dt-seq.(B) Kaplan curve of 
relapse free survival of selected gene, expressed in Versteeg and Seeger microarray datasets r2 amc 
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From literature data both FGFR1 and FZD1 genes are involved in NB 
aggressivnes and differentiating stage [69,70] and cooperates with retinoids in 
tissue development and organogenesis [71,72]. Interesting tyrosine kinase 
receptor FGFR1 has been found to be mutated in NB relaps [73]. The inhibition 
of tyrosine kinase receptors represents promising strategies to cure NB. Taken 
together these findings indicate FGFR1 as the best candidate gene for 
differentiation therapy in combination with ATRA. 
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5. DISCUSSION 
 
NB is a developmental malignancy arising within the neuronal ganglia of the 
peripheral sympathetic nervous system. In the last 25 years, the long-term 
survival for high-risk NB has improved, to reach about 50% [74,75]. So patients 
who have relapsed high-risk NB, remain a significant challenge for physicians 
and researchers, and on balance no curative treatment currently exists. So far, 
there are constant efforts for the development of new therapeutic strategies 
against metastatic NB, with the intention being to definitively prevent late 
recurrence. The clinical use of high doses retinoids after intensive 
chemoradiotherapy (with or without autologous bone marrow transplantation) 
significantly improves event-free survival for high-risk NB patients [1,34, 76]. 
However terapeutic failure that seems to be caused by the drug 
pharmacokinetics or by several biochemical factors highlights an emergent 
demand for novel combination strategies with retinoids to provide more 
therapeutic efficiency [77].  
Hypoxia and HIFs regulate the proliferation and differentiation of different stem 
cell populations including embryonic, neural, and hematopoietic stem cells. 
Cancer stem cells (CSCs) exist as a distinct sub-population in solid tumors and 
hypoxia may enhance their stem cell-like features and make tumors more 
aggressive. In NB, hypoxia downregulates neuronal and neuroendocrine 
differentiation markers and upregulates genes expressed during normal neural 
crest development [57]. Low oxygen levels mediate post-transcriptional 
regulation of the HIF-1α and HIF-2α proteins, this might induce the expression 
of different genes for cell adaptation. The correlation between hypoxia and 
differentiating status grade would suggest that HIF and/or HIF-regulated 
pathways are one of the mechanisms that underline the unresponsiveness to 
differentiation therapy [57, 78]. 
HIF-1α is overexpressed in a wide spectrum of solid tumors even under 
normoxia conditions. The mechanisms that might regulate HIF-1α expression 
and ultimately lead to increased tumor growth and chemoradioresistance are 
different [79, 78]. Otherwise, HIF-2α is more tissue-specific, and it promotes 
the growth of clear-cell renal cell carcinoma (ccRCC) and NB cells, and it is 
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involved in the regulation of stem cell maintenance [49]. Therefore, there is 
increasing interest in the identification of the mechanisms of HIF-1α and HIF-
2α up-regulation in solid tumors, to guide the choice of HIF inhibitors (e.g., 
transcription- or translation-based) that will be best-suited for treatment [81, 
82]. 
In the present study is showed that HIF1A and EPAS1 mRNA levels correlate 
with worse survival in high-risk NB patients, using two different NB microarray 
gene-expression datasets. In both of these datasets, were identified two 
patient subgroups with ‘High’ and ‘Low’ HIF1A and EPAS1 expression levels. 
As a result of the gene ontology analysis, restricted to developmental genes 
that were differentially regulated between these two subgroups for both of the 
datasets, neuronal pathways were more represented in patients with ‘Low’ 
HIF1A or EPAS1 expression, than in those with ‘High’ HIF1A or EPAS1 
expression. This finding suggests that low expression of HIF1A or EPAS1 in 
tumors that are more differentiated, might promote an efficient NB cell 
response to differentiation therapy.  
According to the literature, HIFs gene overexpression in NB solid tumors might 
be determined by several factors, as well as a hypoxic microenvironment. In 
proposed data is shown that the MAPK PI3K-AKT pathways were more 
represented in the patient subgroups with different EPAS1 expression, which 
suggests that these pathways might orchestrate the regulation of the EPAS1 
mRNA in these tumors [64]. Moreover, it is addressed the hypothesis that IL-
1B might up-regulate HIF-1α in patients with NB via a pathway that is 
dependent on nuclear factor kappa B (NFKB) [46]. Also it couldn’t exclude that 
HIF1A and/or EPAS1 expression in solid tumors is regulated by other factors, 
such as genetic/ epigenetic alterations, which were not determined in the this 
study. 
In NB cell lines, low oxygen concentration stabilized HIF-1α and HIF-2α protein 
expression, whereas the HIF1A and EPAS1 mRNA levels decreased. 
However, the increases in the HIF-2α protein levels during hypoxia were only 
modest in comparison to those for HIF-1α protein levels in the same cells. 
These protein increment in hypoxia might result in negative feedback on their 
mRNA production, thus suggesting that high HIF1A and EPAS1 gene 
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expression under normoxic growth conditions might be determined by other 
factors that are not directly linked to the low oxygen concentration. HIF1A and 
EPAS1 mRNA expression in normoxia might reflect the results obtained in-
silico analysis of NB microarrays, so HIF1A and EPAS1 silencing might 
represent a useful therapeutic approach for the treatment of solid tumors with 
high HIF1A and/or EPAS1 mRNA levels. 
In the present study, it was identified a new combination treatment that drives 
glial differentiation and senescence responses in NB cell lines. This treatment 
is based upon the use of HIF1A or EPAS1 gene silencing to enhance ATRA-
induced differentiation proprieties. This mechanism operates in certain cells 
(i.e., the SHSY5Y and SKNBE2c cells) but not in cells that are resistant to 
retinoids (i.e., the SKNAS cells). Achieved results show that single use of 
ATRA induces neurite outgrowth and up-regulation of neural markers, whereas 
in combination with HIF1A or EPAS1 gene silencing it enhances the glial 
phenotype and promotes up-regulation of glial markers. Significantly, even 
with extended co-treatment these cells were driven into ganglion-like clusters, 
resembling less aggressive ganglioneuroma cells. Again it’s possible to 
observe that upon ATRA treatment EPAS1-silenced cells (i.e., NB shEPAS1 
cells) showed an intermediate phenotype between the unsilenced (i.e., the NB 
shCTR cells) and the HIF1A-silenced cells (i.e., the NB shHIF1A cells) which 
suggests that EPAS1 is not the main player in determining neuronal-glial 
transdifferentiation.  
The individual HIF1A or EPAS1 gene silencing was not sufficient to lead 
subdifferentiation into Schwann cells, as also for ATRA used as a single agent, 
which acts independent of Schwann cell differentiation. The combination 
treatments of HIF1A or EPAS1 silencing in the presence of ATRA exclusively 
pushed the NB cells toward transdifferentiation of the neuronal cells into 
Schwann cells. These NB cell lines are characterized by markers of embryonic 
peripheral nervous system development. Therefore these findings suggest that 
HIF1A or EPAS1 (or HIF-related pathways) sustain the activation of alternative 
pathways that can provide Schwann transdifferentiation in NB cells upon 
retinoid treatment. The conversion of NB cells into ganglionic and Schwann 
cells might have great clinical impact in differentiation therapeutic protocols.  
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Pro-senescence therapy has been argued as a promising therapeutic strategy 
for the treatment of cancers. Tumor relapse is the most significant barrier to 
effective therapy and compounds such as the retinoid agents that induce initial 
neuronal differentiation might be not enough in prevention of tumor recurrence. 
The proposed combination therapy can potentially help to reduce NB relapse 
through two main effects: (i) differentiation into a more benign phenotype; and 
(ii) induction of senescence. RA can cause senescence in some NB cells [83, 
84] but it is currently not clear whether senescence represents a significant 
component of its clinical response. Evidence from the literature correlates 
senescence and hypoxia; hypoxia can inhibit or prevent senescence in cells, 
even if the pathways that are altered remain unknown [61]. In proposed NB 
cell system, results show that silencing of HIF1A or EPAS1 expression is 
enough to increase the number of senescent cells independent of the ATRA 
responsiveness, and that the combination of ATRA with HIF1A or EPAS1 
silencing enhances senescent cells in RA-responsive cells. 
Between HIFs, HIF1A is the most promising factor to be silenced to induce 
differentiation in cotreatment with RA, indeed as mentioned before low levels 
of HIF1A are correlated to enrichment of pathway of neuronal differentiation 
(axon guidance), in R2 deposited patients microarray datasets. This finding 
underlines the strong assosiation of HIF1A with differentiative grade of tumor, 
further supporting “our thesis” that pinpoints HIF1A as main driver of failure in 
NB differentiating therapies. 
In solid tumor, there is a different expression of HIF-1α because of oxigen level 
and this peculiarity causes several problem in the use of direct drug compound 
to target it. This study proposes the identification of HIF1A target genes related 
to all tumor area, whose expression is activated or repressed by the presence 
of HIF1A regardless microenviroment, in order to offer new potential attack 
strategies in NB treatment. From the transcriptome analysis (RNA-seq) of 
HIF1A silenced cell line grown in normoxia and hypoxia conditions two gene 
sets (shHIF1A HYP vs shCTR HYP and shHIF1A NX vs shCTR NX) were 
listed, which represent HIF1A target genes in normoxia as in hypoxia 
condition. These results reveled a crucial role of HIF1A in normal oxygen 
conditions, something which, has never been looked at. 
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The absence of HIF1A involves approximately the same pathways (in NX and 
HYP), probably because there are several common genes between the two 
comparisons, except for an enrichment of metabolic pathway in normoxia and 
axon guidance pathway in hypoxia. 
The analysis of HIF1A target genes regulated “exclusively in normoxia” reveals 
that HIF1A affects the expression of genes involved in metabolism and in cell 
energy uptake. Particulary the global gene regulation (72% down vs 28% up) 
in absence of HIF1A underlines the hypotesis that NB cells slow down their 
metabolic activity, thus becaming less proliferating and so less aggressive.  
Gene ontology analysis of HIF1A target genes regulated “exclusively in 
hypoxia” shows an enrichment of axon guidance and cancer pathways, of note 
without global differences in their up and down gene regulation (56%down vs 
44% up). This refects the same results obtained in NB patients with low HIF1A 
expression microrray datasets. 
These new findings point out a role of HIF1A in normoxia conditions. In 
particular in normoxia HIF1A mainly ragulates cell energy intake and metabolic 
activity, whereas in hypoxia HIF1A lack is essential for neuronal differentiation 
pathway. HIF1A-regulated genes, regardless the microenvironment, are 
involved in signal transduction (MAPK signaling), neuronal differentiation and 
cancer pathways. These latest evidences are in line with previously data in NB 
patients with low HIF1A gene expression. Thus, these pathways or genes 
represent canditate targets instead of HIF1A which has been previously 
described, for developing a differentiating therapy in combination with ATRA. 
As shown by WES analysis in last years, high risk NB are characterised by low 
incidence of somatic mutations. Anyway, the low frequencies of mutated genes 
has a grate impact on tumor development because mutations affect important 
biological processes (focal adhesions and regulation of actin cytoskeleton 
pathways) [27]. Targeting mutated genes represents an usefull tool for 
development of novel personalized therapies. Interesting twelve genes 
belonging to “HIF1A target genes” have been previosuly found mutated in NB 
patients. [27]. FGFR1 from RNA-seq analysis is downregulated in NX and HYP 
conditions and its expression is correlated with bad survival in NB patients. 
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Furthermore FGFR1 is tyrosine kinase receptor and its inhibition may 
represents a promising strategies to cure NB. 
 
6. CONCLUSIONS 
 
Taken together, our findings provide the first evidence that HIF1A or EPAS1 
inhibition combined with ATRA treatment can convert NB cells into ganglionic 
and Schwann cells and might also generate a novel trigger for senescence in 
NB RA-responsive cells. Indeed, these data shed new light in the mechanisms 
underlying the neuronal–Schwann cell transdifferentiation process, which 
might represent a model for the development of novel therapeutic strategies 
for patients with high-risk NB [85].  
Recent studies show FGFR1 mutations in NB relaps. From transcriptome 
analysis of silenced HIF1A NB cell line, FGFR1 has been identified as a 
putative druggable HIF1A target. Its regulation independently from 
microenvironment strenghts the hypothesis that FGFR1 is expressed in well-
oxygenated and not-oxygenated areas in solid tumors and so represents the 
best therapeutic target to complitely eradicate the disease. The use of FGFR1 
inhibitors into differentiation therapy protocols might offer therapeutic 
advantages for relapse prevention, which represents a significant barrier that 
needs to be surmounted in therapeutic approaches for patients with high-risk 
NB. 
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7. APPENDICES 
 
 
Figure 7.1. mRNA expression under HIF1A and EPAS1 induction. The HIF1A and EPAS1 induction of the 
expression of CA9, ENO, GLUT-1, GLUT-3, VEGF, EPO, IGF-2 was evaluated by RT-PCR in the SHSY5Y (A), 
SKNBE2c (B) and SKNAS (C) cell lines previously silenced for HIF1A or EPAS1 expression (i.e., shHIF1A or 
shEPAS1, respectively). The data are fold-changes of induction with respect to the shCTR unsilenced cells. The mean 
fold change of 2-(average ∆∆CT) was determined using the mean difference in the ∆CT between the gene expression in the 
shHIF1A or shEPAS1cells and the ∆CT for gene expression in the shCTR cells (as internal control). Data are means 
of three experiments (* P ≤0.05; ** P ≤0.01). 
 
 
 
 
Figure 7.2. ATRA treatment: cell cycle. Unsilenced cells (shCTR) and HIF1A or EPAS1 silenced cells (i.e., shHIF1A 
or shEPAS1, respectively) treated for 6 days with 5 µM and 10 µM ATRA and then processed for flow cytometry using 
propidium iodide. Flow-histograms are shown for the SHSY5Y (A), SKNBE2c (B), SKNAS (C) cells. 
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Table 7.1. Differential gene expression between ‘High’ and ‘Low’ EPAS1 mRNA expression levels. 
 
Versteeg dataset 
 
Seeger dataset 
Gene R-value p-value 
 
Gene R-value p-value 
UNC5C 0.494 0.0007 
 
CITED2 0.598 1.65E-08 
KDR 0.396 0.0381 
 
SH3GL3 -0.473 0.0002 
EYA4 0.396 0.0464 
 
EYA4 0.462 0.0003 
GPC3 0.383 0.0532 
 
SFRP1 0.433 0.0012 
GNA13 -0.400 0.0535 
 
INSM1 0.418 0.0018 
LAMA5 0.373 0.0604 
 
NRG1 -0.420 0.0019 
ESRRG -0.369 0.0635 
 
SMAD1 0.407 0.0025 
EDA2R -0.373 0.0688 
 
DLK1 0.408 0.0028 
TRPC5 -0.354 0.0711 
 
LY6H -0.380 0.0085 
TNFAIP1 0.356 0.0720 
 
GREM1 0.372 0.0112 
SIX5 0.335 0.0721 
 
DCX -0.363 0.0154 
LAMA3 0.340 0.0727 
 
GPR56 -0.357 0.0164 
LAMB1 0.339 0.0730 
 
CYP46A1 -0.358 0.0164 
GATA2 0.358 0.0733 
 
SEMA3D -0.359 0.0167 
HAND1 0.360 0.0737 
 
NELL1 0.343 0.0273 
ANGPTL2 0.335 0.0740 
 
SEMA3A -0.337 0.0312 
LRP5 0.337 0.0749 
 
POU4F1 0.338 0.0318 
ST8SIA4 -0.340 0.0756 
 
PAK3 -0.333 0.0328 
ELN 0.362 0.0758 
 
SMPD1 -0.334 0.0333 
TIMM8A -0.335 0.0758 
 
NGFRAP1 -0.329 0.0347 
TLL2 -0.332 0.0759 
 
POU4F2 0.330 0.0357 
WIF1 -0.341 0.0761 
 
ITGA8 -0.327 0.0366 
SPP1 -0.342 0.0795 
 
HECA 0.320 0.0461 
ETS2 0.343 0.0796 
 
SMPD3 -0.318 0.0470 
DLL1 0.344 0.0799 
 
IL18 -0.313 0.0510 
TFAP2B 0.349 0.0821 
 
UNC5C 0.314 0.0517 
EBF4 0.344 0.0843 
 
DKK1 0.314 0.0531 
FOXO1 0.346 0.0858 
 
PKD2 0.308 0.0587 
EMD -0.323 0.0904 
 
CHODL 0.307 0.0593 
ACVRL1 0.324 0.0920 
 
CDH11 -0.306 0.0604 
ENG 0.325 0.0924 
 
TBR1 -0.304 0.0615 
SEMA3D -0.325 0.0955 
 
SLIT3 0.302 0.0636 
INSM1 0.319 0.0989 
 
DDX47 0.302 0.0653 
ACVR1 0.315 0.1001 
 
SPOCK2 -0.295 0.0768 
NPR3 0.319 0.1006 
 
SEMA6D -0.294 0.0773 
MYH9 0.317 0.1015 
 
PAPSS1 0.292 0.0778 
OPHN1 -0.316 0.1017 
 
EXT2 -0.295 0.0787 
SFRP1 0.316 0.1033 
 
TRPC5 -0.292 0.0798 
TSHZ1 0.312 0.1099 
 
HDAC9 0.290 0.0807 
PRKAR1A -0.306 0.1142 
 
LAMB1 0.288 0.0838 
AGT 0.308 0.1150 
 
ZEB2 0.286 0.0899 
COL18A1 0.305 0.1151 
 
PLXNA3 -0.282 0.0986 
SIX3 -0.306 0.1161 
 
KALRN -0.277 0.1143 
FZD4 0.308 0.1172 
 
HRAS -0.276 0.1158 
BEX1 -0.309 0.1174 
 
FGF14 0.273 0.1233 
EPHB4 0.307 0.1178 
 
ETS2 0.273 0.1256 
PKD2 0.302 0.1233 
 
PHGDH 0.268 0.1265 
KCNQ2 0.301 0.1262 
 
BTG1 0.268 0.1269 
FGFR3 0.300 0.1284 
 
DHCR24 -0.269 0.1278 
LFNG 0.298 0.1322 
 
PSME4 0.267 0.1285 
SPEG 0.296 0.1380 
 
ROBO3 0.271 0.1287 
AGPAT6 0.291 0.1421 
 
HHAT 0.270 0.1295 
FLII 0.291 0.1438 
 
CMKLR1 -0.269 0.1296 
NGRN -0.294 0.1440 
 
STMN1 -0.258 0.1306 
HRAS -0.290 0.1443 
 
RELN 0.265 0.1313 
SOSTDC1 -0.291 0.1460 
 
AES 0.269 0.1315 
COL4A2 0.286 0.1461 
 
CCL2 -0.259 0.1321 
NOTCH3 0.293 0.1462 
 
GAL 0.265 0.1323 
SLIT3 0.292 0.1473 
 
TWIST1 0.259 0.1328 
STAB1 0.286 0.1483 
 
SEMA6A -0.259 0.1335 
LSR 0.286 0.1492 
 
SERPINI1 0.264 0.1335 
ERG 0.292 0.1494 
 
SMARCA1 -0.263 0.1336 
ADAM18 -0.284 0.1494 
 
ACVR1 0.259 0.1343 
GJA5 0.287 0.1497 
 
NME5 -0.261 0.1350 
DLL4 0.284 0.1503 
 
KLF3 0.260 0.1353 
SMAD1 0.288 0.1504 
 
PBXIP1 0.261 0.1363 
COL15A1 0.287 0.1507 
 
COL9A2 -0.256 0.1370 
TSHZ3 0.287 0.1520 
 
NGFR -0.260 0.1372 
ERC2 -0.281 0.1521 
 
MARK2 -0.262 0.1372 
DAB2 0.283 0.1529 
 
NLGN1 0.261 0.1375 
ENPEP 0.281 0.1534 
 
PHYH 0.256 0.1378 
FRZB 0.280 0.1541 
 
EYA1 0.254 0.1425 
FZD8 0.282 0.1546 
 
PRKRA 0.253 0.1446 
SEMA5A 0.281 0.1554 
 
TCF12 0.253 0.1448 
ANGPT1 0.278 0.1613 
 
GRSF1 0,252 0.1465 
PRELP 0.278 0.1618 
 
TRIM3 -0.251 0.1495 
NPR1 0.277 0.1631 
 
TLE2 0.249 0.1504 
BDNF -0.276 0.1634 
 
SEMA4D 0.250 0.1512 
TBX2 -0.272 0.1840 
 
CTNND2 -0.249 0.1523 
SNCA -0.271 0.1877 
 
CDK5RAP3 -0.248 0.1544 
ZIC2 -0.270 0.1879 
 
SLIT2 -0.246 0.1609 
SVIL 0.270 0.1896 
 
SKIL -0.246 0.1626 
NRP1 0.268 0.1897 
 
SEPP1 -0.244 0.1679 
ST8SIA2 0.268 0.1916 
 
RTN1 -0.243 0.1710 
SOX9 -0.269 0.1919 
 
CDKN1B 0.243 0.1723 
HOXC9 0.267 0.1944 
 
GAP43 -0.241 0.1766 
PLXND1 0.264 0.2080 
 
GADD45G -0.241 0.1770 
FLNA 0.264 0.2101 
 
PFN1 0.239 0.1832 
MPPED2 -0.254 0.2170 
 
VCAN -0.238 0.1837 
WFS1 0.255 0.2183 
 
IL7 -0.238 0.1840 
SEMA4C 0.254 0.2185 
 
PPARD 0.236 0.1910 
ID1 0.260 0.2186 
 
JMJD6 -0.235 0.1946 
HSPB2 0.261 0.2186 
 
UGDH 0.235 0.1951 
ZEB2 0.260 0.2187 
 
CHRM3 0.234 0.1965 
MMP2 0.261 0.2192 
 
STMN2 -0.234 0.1979 
VEZF1 -0.260 0.2193 
 
PTPRR 0.233 0.1991 
POFUT1 0.255 0.2199 
 
MYH6 -0.232 0.1998 
TUBD1 -0.257 0.2215 
 
SPRY2 -0.232 0.2002 
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SNTG2 0.255 0.2218 
 
TFIP11 0.231 0.2017 
ELK3 0.250 0.2220 
 
TP53BP2 0.231 0.2048 
FEZ1 -0.256 0.2223 
 
PAPSS2 0.226 0.2286 
COL6A3 0.255 0.2227 
 
FGF9 -0.226 0.2293 
HDAC4 0.255 0.2228 
 
ACP2 -0.225 0.2329 
GRSF1 0.256 0.2232 
 
HBEGF -0.224 0.2332 
JAG1 0.258 0.2234 
 
PCOLCE 0.223 0.2386 
MAML3 0.250 0.2236 
 
PPP1R9A -0.223 0.2404 
MYH11 0.257 0.2237 
 
TLX3 0.221 0.2491 
APAF1 0.258 0.2239 
 
BRAF -0.221 0.2503 
FGF5 -0.256 0.2240 
 
NUMB -0.219 0.2552 
CITED2 0.256 0.2243 
 
CREG1 -0.218 0.2559 
SKI 0.250 0.2246 
 
SEMA3E -0.218 0.2572 
SIM2 -0.251 0.2250 
 
SH2B3 -0.217 0.2573 
THY1 0.257 0.2256 
 
IFRD1 -0.217 0.2590 
PPARD 0.250 0.2257 
 
DIXDC1 0.218 0.2594 
SOX11 -0.250 0.2259 
 
LEFTY2 -0.217 0.2602 
PBXIP1 0.251 0.2268 
 
CACNB2 -0.215 0.2606 
AR 0.251 0.2271 
 
NEO1 -0.215 0.2623 
MLF1 -0.252 0.2278 
 
KRT19 -0.215 0.2628 
ITGB5 0.250 0.2278 
 
PNMA1 -0.216 0.2635 
FOXK1 0.251 0.2286 
 
TIMP1 -0.213 0.2677 
LMO1 0.246 0.2315 
 
NES 0.213 0.2682 
PLXNA1 0.245 0.2328 
 
DDX41 0.214 0.2690 
DLK1 0.247 0.2328 
 
PAX9 0.212 0.2723 
NPTN -0.246 0.2333 
 
CALCA -0.210 0.2854 
TBX5 -0.245 0.2335 
 
MFN2 -0.210 0.2865 
UNC5B 0.246 0.2341 
 
DACH1 0.208 0.2924 
SRF 0.245 0.2341 
 
TRO -0.208 0.2954 
TSHZ2 0.247 0.2343 
 
THRA -0.207 0.2971 
HTN3 -0.245 0.2345 
 
TPP1 -0.207 0.2976 
HEYL 0.247 0.2350 
 
NRP2 -0.207 0.2994 
SPATA18 -0.243 0.2436 
    
NES 0.242 0.2439 
    
NELL1 0.241 0.2450 
    
ADAM10 0.241 0.2452 
    
HOXD8 -0.242 0.2455 
    
FLNB 0.242 0.2471 
    
DGCR2 0.240 0.2492 
    
SHC3 -0.240 0.2500 
    
EYA1 0.239 0.2544 
    
LHX6 0.238 0.2561 
    
MEA1 -0.237 0.2562 
    
PAPSS2 0.237 0.2573 
    
SPARC 0.237 0.2580 
    
NGFRAP1 -0.236 0.2611 
    
POU4F2 0.235 0.2611 
    
AHNAK 0.234 0.2612 
    
ROBO4 0.235 0.2623 
    
KLK6 -0.234 0.2627 
    
QKI -0.236 0.2627 
    
DVL3 0.233 0.2635 
    
COL1A1 0.236 0.2638 
    
ITGA11 0.232 0.2641 
    
RREB1 0.234 0.2645 
    
FGF10 -0.233 0.2652 
    
NTNG1 -0.232 0.2653 
    
IGFBP4 0.232 0.2656 
    
CCK -0.232 0.2665 
    
TRAF4 -0.232 0.2669 
    
ANPEP 0.228 0.2673 
    
NR5A2 0.228 0.2674 
    
TLE3 0.232 0.2684 
    
SERPINE2 0.228 0.2687 
    
AFF3 0.228 0.2688 
    
COL3A1 0.229 0.2688 
    
FABP7 -0.229 0.2701 
    
SNAI2 0.229 0.2712 
    
MYT1 0.230 0.2722 
    
CHUK -0.229 0.2726 
    
AEBP1 0.230 0.2736 
    
SH3GL3 -0.229 0.2736 
    
CALCRL 0.229 0.2739 
    
COL1A2 0.229 0.2752 
    
POU3F3 -0.226 0.2776 
    
SLC30A1 0.226 0.2778 
    
TGIF1 0.225 0.2811 
    
VEGFC 0.225 0.2815 
    
DLX2 -0.224 0.2864 
    
INSR 0.223 0.2887 
    
ITGA2 0.223 0.2895 
    
TCL1A 0.222 0.2916 
    
TFIP11 0.222 0.2922 
    
DKK2 -0.221 0.2924 
    
DCTN1 0.222 0.2925 
    
SEMA5B 0.221 0.2931 
    
DGKD 0.221 0.2955 
    
DOPEY2 0.220 0.2978 
    
MOV10 0.220 0.2989 
    
DACH1 0.219 0.2995 
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Table7 2. Differential gene expression between ‘High’ and ‘Low’ HIF1A mRNA expression levels. 
 
Versteeg dataset 
  Seeger dataset 
Gene  R-Value P-value  Gene R-value p-value 
JMJD6 0.582 0.00000  GMFB 0.396 0.0050 
NTRK1 -0.515 0.00020  KCNQ2 -0.393 0.0051 
ROR2 0.499 0.00035  RELN 0.397 0,0054 
NRCAM -0.490 0.00036  PTHLH 0.400 0.0055 
SPRED2 0.486 0.00038  ATXN3 0.389 0.0055 
B3GNT5 0.492 0.00040  CNTFR -0.386 0.0059 
HMX1 -0.479 0.00046  APBA1 -0.401 0.0060 
SIX3 0.458 0.00125  HDAC5 -0.383 0.0063 
RNF113A 0.455 0.00135  NUMB 0.418 0.0063 
INSRR -0.448 0.00168  FRAT2 -0.379 0.0068 
DLX6 0.439 0.00191  TCF25 -0.376 0.0068 
MAFF 0.440 0.00193  ZNF267 0.377 0.0071 
PLXNC1 -0.443 0.00195  BRSK2 -0.402 0.0073 
IL7 -0.436 0.00203  MTR 0.370 0.0076 
RAPGEF5 -0.441 0.00205  C1GALT1 0.371 0.0076 
SHC3 0.434 0.00212  CUL7 -0.372 0.0076 
VPRBP 0.425 0.00275  ATR 0.428 0.0077 
APBA1 -0.420 0.00281  DRD2 -0.366 0.0081 
NR2F1 0.425 0.00286  GLRB -0.405 0.0083 
EIF2B2 0.426 0.00288  LIF 0.366 0.0084 
ACHE -0.421 0.00290  APBA2 -0.362 0.0089 
TRERF1 -0.421 0.00301  UGDH 0.362 0.0091 
RET 0.421 0.00307  STMN3 -0.360 0.0092 
SOX6 -0.412 0.00381  EGR3 0.357 0.0099 
RBBP7 0.409 0.00382  CHUK 0.351 0.0116 
GPI 0.409 0.00390  HMX1 -0.351 0.0121 
SCN8A -0.412 0.00394  SIAH1 -0.352 0.0121 
PRPS1 0.409 0.00405  SOX15 -0.349 0.0122 
SH2D2A -0.406 0.00422  ELF3 0.348 0.0124 
AMIGO1 -0.404 0.00425  MARK4 -0.344 0.0140 
CXCR4 0.405 0.00434  SFRP4 0.341 0.0155 
PCOLCE 0.401 0.00477  RBBP7 0.337 0.0174 
PHLDA2 0.398 0.00520  NR2F1 0.334 0.0178 
INVS 0.395 0.00557  SOX9 0.328 0.0181 
NRSN1 -0.396 0.00557  C16orf80 -0.335 0.0181 
DLX5 0.395 0.00567  GTF2IRD1 -0.334 0.0181 
GSS 0.390 0.00647  NR5A2 0.329 0.0181 
PROK1 -0.387 0.00728  EIF2AK3 0.329 0.0181 
SLIT1 0.385 0.00785  LEPR 0.330 0.0182 
EXT2 0.383 0.00821  MBNL1 0.334 0.0185 
HOXC4 -0.382 0.00826  PRKAR1A 0.331 0.0185 
FREM1 -0.379 0.00902  CRMP1 -0.331 0.0186 
HHAT 0.376 0.00977  ACVR1B -0.332 0.0186 
QKI 0.376 0.00990  ARHGAP24 0.330 0.0187 
PLCE1 0.374 0.00998  NTRK2 0.325 0.0197 
HES6 0.374 0.01001  MAEA -0.325 0.0199 
CITED1 0.375 0.01010  DGCR2 -0.320 0.0235 
TSHZ2 -0.372 0.01022  NCAM1 -0.319 0.0236 
KEAP1 0.373 0.01026  INA -0.317 0.0250 
KIF1B -0.371 0.01035  TNFSF11 0.316 0.0254 
SPEG -0.370 0.01058  PAFAH1B3 -0.314 0.0260 
RNF103 -0.369 0.01075  BICC1 0.315 0.0262 
NHLH2 0.368 0.01080  MEGF8 -0.313 0.0267 
CRABP1 0.367 0.01084  TFAP2B -0.311 0.0272 
SIX2 0.368 0.01089  PDGFC 0.312 0.0273 
KRT19 -0.369 0.01093  DPYSL3 -0.312 0.0274 
TEAD4 0.367 0.01101  ARNT2 -0.308 0.0300 
FAM132B 0.366 0.01114  CXCL1 0.307 0.0301 
EBF4 -0.364 0.01124  SPEG -0.306 0.0308 
TWIST1 0.364 0.01131  CRKL -0.305 0.0319 
VCAN 0.365 0.01132  GATA2 -0.304 0.0321 
TMOD2 -0.364 0.01135  AGT 0.301 0.0358 
ITGA8 -0.362 0.01165  HOXD4 0.297 0.0410 
PCDHB12 -0.362 0.01166  PLXNA1 -0.296 0.0416 
GRHL1 -0.359 0.01168  AES -0.295 0.0419 
LMO4 0.361 0.01180  FLT1 0.292 0.0454 
APBA2 -0.360 0.01181  BDNF 0.291 0.0470 
NDRG4 -0.359 0.01181  PCDHB11 -0.291 0.0473 
PAPSS1 0.359 0.01190  TNFRSF12A 0.288 0.0499 
CSRP2 0.360 0.01193  BTG1 0.288 0.0501 
TGFB2 0.359 0.01196  THBD 0.285 0.0548 
FZD7 0.361 0.01198  HHEX 0.284 0.0551 
SEMA3F 0.356 0.01244  FZD7 0.283 0.0573 
SPATA18 0.356 0.01255  NEURL -0.282 0.0582 
GDF11 -0.356 0.01262  CALCA 0.280 0.0603 
PCDHB15 -0.353 0.01370  CLPTM1 -0.280 0.0603 
MIB1 -0.350 0.01508  TGFB3 0.279 0.0617 
MMP2 0.348 0.01611  SPG7 -0.277 0.0623 
FEZ1 0.347 0.01673  MATN3 0.278 0.0629 
CHST9 -0.346 0.01675  NTRK1 -0.277 0.0629 
HESX1 0.346 0.01686  PTEN 0.278 0.0632 
MSH6 0.344 0.01764  PRMT1 -0.275 0.0641 
ZBTB16 -0.343 0.01803  GRIK1 0.275 0.0645 
ZMYM4 -0.340 0.02018  QKI 0.274 0.0649 
EBF1 -0.339 0.02060  CTNNB1 0.275 0.0650 
TLL2 0.337 0.02113  EYA2 0.273 0.0650 
FKBP4 0.338 0.02121  DCN 0.275 0.0652 
NEURL -0.337 0.02154  SMPD3 -0.273 0.0655 
TBX20 -0.333 0.02430  HSD11B1 0.271 0.0690 
PDGFRA 0.332 0.02441  PTMS -0.269 0.0732 
NINJ1 0.331 0.02511  DOK4 -0.268 0.0743 
POU3F1 -0.331 0.02519  GPR65 0.268 0.0748 
DACT1 0.330 0.02579  SEMA3C 0.267 0.0752 
WNT3 0.328 0.02682  FBN2 0.267 0.0754 
CYFIP1 0.327 0.02779  SLC30A1 0.266 0.0754 
SPHK1 0.327 0.02805  KEAP1 -0.266 0.0758 
PRRX2 0.324 0.02969  LAMA2 0.264 0.0783 
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SRF 0.324 0.02988  CA10 -0.263 0.0812 
CHODL 0.323 0.03039  SEMA5A 0.261 0.0813 
FOXC1 0.322 0.03078  PHOX2B -0.261 0.0820 
NRP1 -0.322 0.03084  SVIL 0.262 0.0821 
CTNND2 -0.322 0.03085  CD164 0.261 0.0821 
VANGL2 -0.320 0.03210  NDRG4 -0.262 0.0825 
FZD2 0.320 0.03227  DIXDC1 -0.261 0.0828 
SHB 0.319 0.03269  EFNB3 -0.261 0.0833 
ALK 0.319 0.03309  FZD3 -0.257 0.0842 
DDX1 0.318 0.03363  FYN -0.259 0.0845 
FGF14 0.317 0.03405  C4orf6 0.257 0.0850 
HUS1 0.316 0.03429  CTNND2 -0.257 0.0850 
DRD2 -0.316 0.03460  ITGB1 0.259 0.0850 
GATA2 -0.316 0.03471  ZFP36L1 0.256 0.0854 
UGDH 0.315 0.03483  EDAR 0.257 0.0855 
DNER -0.315 0.03499  TGFBR3 0.258 0.0861 
ZNF22 0.315 0.03528  MAPT -0.258 0.0869 
CEBPB 0.312 0.03729  FUT8 0.255 0.0870 
ARVCF -0.310 0.04016  ARC 0.255 0.0883 
ARHGAP22 -0.309 0.04025  LMO1 -0.254 0.0893 
SOX4 -0.309 0.04025  MT3 0.254 0.0895 
SALL1 -0.310 0.04043  VPRBP 0.253 0.0911 
GRSF1 0.307 0.04287  AHNAK 0.252 0.0921 
PHGDH 0.307 0.04293  GATA3 -0.249 0.1008 
HEXB 0.303 0.04704  PBX1 -0.248 0.1017 
DRP2 0.303 0.04765  GNAO1 -0.247 0.1045 
AQP4 -0.301 0.04915  GSS 0.247 0.1045 
SBF2 -0.301 0.04929  RYK 0.247 0.1048 
LIMD1 0.300 0.04944  WNT5A 0.246 0.1054 
STRBP 0.300 0.04959  SCMH1 -0.242 0.1065 
HOXB4 0.300 0.04975  PLXNB2 -0.245 0.1067 
DSCAM 0.300 0.05010  SMAD1 -0.242 0.1069 
CNTN4 0.298 0.05228  TTPA 0.245 0.1070 
BMPR2 -0.298 0.05248  MCL1 0.242 0.1072 
GJA1 0.297 0.05281  SEMA3E 0.242 0.1073 
HOXA4 0.297 0.05304  TRO -0.244 0.1074 
NCL 0.296 0.05311  THRA -0.244 0.1075 
PRMT1 0.296 0.05342  GAS7 0.245 0.1075 
TIMP1 0.296 0.05363  TNFRSF11B 0.245 0.1076 
CNTFR -0.295 0.05511  PLXNB1 -0.243 0.1077 
AATF 0.294 0.05521  ARVCF -0.242 0.1079 
MYCNOS 0.294 0.05527  PDPN 0.244 0.1080 
DDX47 0.294 0.05534  CREG1 0.241 0.1085 
PRELID1 0.293 0.05581  FGFR1 0.242 0.1086 
CA10 -0.290 0.06053  ACVR1 0.243 0.1087 
PMP22 -0.289 0.06185  PBX3 -0.239 0.1093 
LAMA3 -0.289 0.06264  HOXB7 0.239 0.1100 
EPHB1 0.287 0.06385  NFATC1 0.238 0.1100 
SNTG2 -0.287 0.06417  SEMA7A 0.240 0.1103 
MACF1 -0.287 0.06435  HTATIP2 0.238 0.1103 
CAPN3 -0.286 0.06543  SEMA3B 0.238 0.1104 
FYN -0.286 0.06618  BMPR1B -0.240 0.1104 
PTTG1IP 0.285 0.06731  MYL6B -0.240 0.1107 
MYT1L -0.284 0.06814  SGCB -0.238 0.1111 
PITX1 0.284 0.06880  DNM1L -0.239 0.1113 
WWP1 -0.283 0.07059  DCTN1 -0.237 0.1118 
WNT5B 0.282 0.07092  TP53BP2 0.237 0.1124 
EXT1 0.280 0.07444  AHCTF1 0.236 0.1126 
ADAMTS9 0.278 0.07654  LECT2 0.237 0.1127 
APBB2 0.278 0.07687  HAND2 -0.236 0.1128 
SCG2 -0.279 0.07700  NTNG1 0.236 0.1129 
MTSS1 -0.278 0.07730  PIAS4 -0.236 0.1129 
ACVR2A -0.278 0.07756  ERC1 -0.235 0.1139 
MYCN 0.277 0.07900  NPTX1 0.234 0.1151 
EPHB2 0.276 0.07953  RNF103 -0.233 0.1184 
PNMA1 0.276 0.07987  NR4A3 0.233 0.1186 
KIAA1715 -0.275 0.08132  LGR4 0.233 0.1192 
MYT1 -0.275 0.08245  NDP 0.233 0.1196 
BZW2 0.273 0.08489  DOC2A -0.231 0.1212 
ASB1 0.273 0.08519  LHX3 0.231 0.1213 
PCDHA3 -0.273 0.08522  ADAM10 0.231 0.1215 
TFAP2B -0.273 0.08538  PHC3 0.231 0.1215 
NRGN 0.272 0.08649  CRIM1 0.231 0.1216 
SIX4 0.271 0.08873  MPZ 0.229 0.1251 
NAIP -0.270 0.08885  SEMA4C -0.229 0.1264 
ELAVL3 0.270 0.09064  LGALS3 0.226 0.1285 
DZIP1 0.269 0.09146  MKL2 0.226 0.1291 
EDF1 0.268 0.09412  LECT1 0.227 0.1296 
CBLN1 0.267 0.09544  SRI -0.228 0.1296 
CALCRL -0.267 0.09580  TMOD2 -0.227 0.1296 
MST1R -0.266 0.09648  PCDHB6 -0.227 0.1299 
RACGAP1 0.265 0.09821  NAPA -0.227 0.1301 
KALRN 0.265 0.09825  DHCR24 0.227 0.1305 
MAEA 0.265 0.09849  EDA 0.225 0.1327 
CHERP 0.265 0.09858  BIN1 -0.224 0.1336 
HOXD3 0.265 0.09867  TNFAIP1 -0.225 0.1338 
POMT1 -0.264 0.09871  MAPK12 -0.223 0.1360 
ATR 0.263 0.10080  LIMD1 0.223 0.1363 
WNT4 -0.263 0.10086  BMP1 -0.223 0.1365 
PDPN 0.262 0.10108  MID1 -0,223 0.1371 
JPH1 0.263 0.10115  GJA1 0.222 0.1377 
FES 0.263 0.10140  APLP1 -0.222 0.1378 
SEMA6C -0.262 0.10157  GHR 0.222 0.1384 
GAL 0.261 0.10264  EMP1 0.222 0.1386 
IL8 0.261 0.10355  ATP6AP1 -0.221 0.1409 
NMUR2 -0.260 0.10363  CXCR4 0.220 0.1419 
RORB -0.261 0.10364  SMAD3 0.220 0.1421 
FMN2 -0.260 0.10413  MTSS1 -0.220 0.1421 
ALDH3A2 -0.259 0.10482  NRCAM -0.220 0.1422 
SEMA3E -0.259 0.10533  AMOT 0.218 0.1451 
HAND2 -0.259 0.10580  PRKRA -0.218 0.1452 
CANX 0.258 0.10648  NOTCH2 0.218 0.1454 
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TUBD1 0.258 0.10690  NES -0.218 0.1456 
VAX2 0.258 0.10724  HMGCR 0.218 0.1457 
TRIM54 0.257 0.10741  VLDLR 0.217 0.1479 
NFE2 -0.258 0.10785  RAI2 0.216 0.1480 
TGFB3 0.257 0.10817  NRL 0.216 0.1483 
MITF 0.257 0.10834  ANPEP 0.217 0.1487 
SOX11 0.256 0.10958  ILK -0.216 0.1489 
FGF11 0.256 0.10985  GATA6 0.216 0.1491 
DLL3 0.255 0.11035  PTN 0.214 0.1527 
CRYGD 0.255 0.11046  TAGLN3 -0.215 0.1528 
EIF2B5 0.255 0.11086  MYT1 -0.214 0.1535 
PSME4 0.255 0.11089  MAPK1 -0.214 0.1541 
CTNNBIP1 -0.254 0.11102  CTNNBIP1 -0.213 0.1567 
EIF2AK3 0.255 0.11105  PTS -0.212 0.1596 
ECE2 -0.254 0.11151  EREG 0.212 0.1596 
FGF2 0.254 0.11185  HAND1 -0.211 0.1604 
LAMA4 -0.253 0.11206  GNRH1 0.210 0.1658 
TP53 0.253 0.11258  YWHAH -0.210 0.1666 
ITGA2 0.253 0.11401  RASA1 0.209 0.1681 
GFRA3 -0.252 0.11440  MDK -0.208 0.1697 
SMAD3 0.252 0.11445  DRG1 -0.207 0.1704 
FZD5 0.251 0.11733  NEUROD1 0.207 0.1706 
BMPR1A 0.250 0.11872  POGK -0.208 0.1706 
UNC5D -0.250 0.11934  DMD 0.208 0.1708 
ANGPTL4 0.250 0.11968  ZMYM4 -0.208 0.1709 
MEOX1 -0.250 0.11983  DCLK1 -0.207 0.1710 
MCL1 0.249 0.11994  CACNA1A 0.206 0.1712 
EGR3 0.249 0.12135  STX2 -0.208 0.1713 
E2F5 0.248 0.12247  F2 0.207 0.1713 
DHCR7 0.248 0.12280  SEMA4F -0.206 0.1714 
CNTN2 0.247 0.12411  BMP10 0.206 0.1716 
SOX9 0.247 0.12478  TOP1 0.206 0.1718 
CFC1 0.247 0.12531  NRP2 -0.205 0.1725 
SH3GL1 0.246 0.12547  BAX -0.205 0.1730 
NEUROD1 0.246 0.12579  TRIM3 -0.205 0.1733 
STMN2 -0.245 0.12747  NDUFV2 -0.205 0.1737 
FHL3 0.245 0.12760  FOXO4 0.204 0.1752 
SMAD5 -0.245 0.12762  ADAMTS9 0.204 0.1755 
FLNB 0.244 0.13045  SEMA4D -0.204 0.1757 
HECA -0.243 0.13439  IL8 0.204 0.1760 
ACSBG1 -0.242 0.13493  ROBO3 -0.203 0.1765 
HOXD9 0.242 0.13546  MYT1L -0.202 0.1788 
EMD 0.242 0.13577  DKK1 0.202 0.1789 
GLRB -0.241 0.13690  SPHK2 -0.203 0.1791 
HMGB3 0.241 0.13772  EGR2 0.201 0.1849 
HTATIP2 0.240 0.14007  ANGPTL4 0.199 0.1926 
ENC1 0.239 0.14218  WWP1 0.198 0.1942 
DACH1 0.239 0.14220  FZD6 0.198 0.1952 
DLK1 0.239 0.14341  PGF 0.198 0.1954 
CLDN11 0.238 0.14426  RACGAP1 0.198 0.1957 
ERCC2 0.238 0.14473  PTMA 0.197 0.1966 
CENPF 0.237 0.14576  TMPRSS6 0.197 0.1972 
PBX3 0.237 0.14641  TAL1 0.197 0.1977 
CHRDL2 0.236 0.14816  DGAT1 -0.196 0.1980 
LAMA1 0.235 0.15238  PPAP2B 0.196 0.2009 
IRS2 0.235 0.15245  PHLDA2 0.194 0.2022 
ANGPT2 0.234 0.15342  OPHN1 0.193 0.2027 
YWHAH -0.234 0.15371  MPPED2 -0.194 0.2029 
PKD2 0.234 0.15382  SOX2 0.194 0.2031 
PTCH1 0.234 0.15387  DICER1 0.194 0.2033 
ANGPTL2 0.234 0.15408  NF1 -0.193 0.2034 
GCNT2 -0.234 0.15436  THBS1 0.194 0.2036 
AXIN2 0.233 0.15505  PIK3CB 0.193 0.2037 
MTL5 -0.233 0.15528  EBF2 0.192 0.2037 
BVES 0.233 0.15545  EXT1 0.192 0.2037 
MAML3 -0.233 0.15555  ZEB2 0.194 0.2039 
FXR1 0.232 0.15627  MSX1 0.192 0.2039 
RNH1 0.232 0.15674  OVOL2 0.194 0.2041 
MARK4 0.231 0.15887  LUC7L -0.193 0.2042 
COL11A2 -0.231 0.15937  BMPR1A 0.192 0.2043 
NDE1 0.231 0.15940  CASP7 0.193 0.2045 
FUT10 0.231 0.15940  CDK5RAP1 0.194 0.2047 
LOX 0.231 0.15948  NGRN -0.194 0.2054 
MXD1 -0.230 0.16084  TLX2 -0.191 0.2058 
CCNF 0.229 0.16404  DGKD -0.191 0.2061 
ATRNL1 -0.229 0.16436  MAP1S -0.194 0.2061 
THRA -0.229 0.16460  FOXC1 0.191 0.2062 
SIAH2 0.229 0.16487  ZNF3 -0.191 0.2066 
EHF -0.228 0.16603  ISL1 -0.191 0.2069 
LEFTY1 -0.228 0.16658  EIF2B2 0.191 0.2070 
WDR5 0.227 0.16701  SIX2 0.191 0.2071 
THBD 0.227 0.16735  CDK5 -0.190 0.2095 
HRAS 0.227 0.16750  NGFR 0.189 0.2098 
PSEN2 0.227 0.16769  SPP1 0.189 0.2102 
PBX1 -0.226 0.16781  NDRG2 -0.189 0.2103 
NHLH1 0.226 0.16781  MYCNOS 0.189 0.2104 
AZU1 -0.227 0.16786  ITGB7 0.189 0.2104 
MYH3 -0.225 0.17132  SPON1 0.189 0.2109 
COL13A1 0.225 0.17218  ANGPTL3 0.188 0.2115 
ZNF256 0.223 0.17691  GNRHR 0.187 0.2139 
F2R 0.223 0.17706  JARID2 -0.188 0.2142 
HOXD10 0.223 0.17713  L1CAM -0.187 0.2146 
EYA2 0.224 0.17722  NR4A2 0.187 0.2161 
DIP2A -0.223 0.17789  ODAM 0.187 0.2163 
DAZAP1 0.223 0.17796  OLIG2 0.186 0.2174 
MNT 0.222 0.17908  GADD45B 0.186 0.2184 
KLF5 -0.222 0.17925  FZD1 0.185 0.2207 
ZNF7 0.222 0.17966  SPHK1 0.185 0.2234 
TCF12 0.221 0.18073  MMP19 0.184 0.2244 
ETV5 0.221 0.18075  CDK5R1 -0.184 0.2257 
MAPT -0.221 0.18082  MMP11 -0.184 0.2259 
TIMM8A 0.221 0.18095  PHC1 -0.182 0.2288 
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CHD5 -0.221 0.18129  PIM1 0.183 0.2291 
CHRD -0.221 0.18142  NHLH2 0.183 0.2299 
ALDH5A1 0.220 0.18190  PAX2 0.182 0.2305 
RYK 0.220 0.18253  MYL1 0.183 0.2306 
ID2 0.220 0.18292  MEF2C 0.182 0.2321 
PROK2 0.219 0.18437  ZBTB17 -0.181 0.2322 
CHKB -0.219 0.18504  WNT6 0.180 0.2369 
COL4A4 -0.218 0.18784  CRYGC -0.180 0.2375 
ERBB3 -0.218 0.18786  MITF 0.180 0.2375 
WNT6 0.217 0.18948  REG3A 0.180 0.2377 
ERBB4 0.218 0.18963  DPYSL4 -0.179 0.2397 
EIF2B4 0.217 0.19228  FHL1 -0.179 0.2401 
LAMB1 0.216 0.19279  RNH1 -0.179 0.2402 
LY6H 0.216 0.19313  RET 0.177 0.2460 
EPO -0.216 0.19340  KDR 0.177 0.2464 
TBX2 0.216 0.19380  ELAVL1 0.178 0.2465 
C11orf73 0.215 0.19417  AGGF1 -0.177 0.2468 
DNASE2 0.215 0.19449  IL23A -0.177 0.2469 
RELA 0.215 0.19504  GPM6B 0.177 0.2473 
SMO 0.214 0.19955  STIL 0.177 0.2475 
LMO1 -0.214 0.19979  NEUROD4 0.177 0.2476 
LETM1 0.213 0.19991  DAZAP1 0.176 0.2479 
MAPK1 -0.214 0.19991  DOPEY2 -0.175 0.2517 
FOXD3 -0.213 0.20344  TRPS1 0.175 0.2523 
GLDN 0.212 0.20548  XAB2 -0.175 0.2529 
AFF3 -0.212 0.20557  HEXB 0.174 0.2539 
IFRD1 -0.212 0.20582  HPCAL4 -0.175 0.2539 
PAK3 -0.212 0.20584  SRF 0.174 0.2563 
PKP2 -0.211 0.20686  SPRED2 0.173 0.2595 
PTP4A1 -0.211 0.20708  GNA13 -0.172 0.2646 
LGALS1 0.210 0.20986  HEY1 0.172 0.2647 
CCM2 -0.210 0.20995  APBB2 0.172 0.2648 
SORT1 0.210 0.21009  DCX -0.171 0.2660 
FZD6 0.210 0.21018  CHRDL1 0.171 0.2665 
SH3GL2 0.209 0.21251  PDGFRA 0.171 0.2667 
RPS6KA6 0.209 0.21293  PDE3B 0.171 0.2672 
ARC 0.209 0.21310  CSPG5 -0.169 0.2759 
FGF1 0.208 0.21431  BMP2 0.169 0.2761 
AES -0.208 0.21493  IRS2 -0.169 0.2767 
TRIM3 -0.207 0.21732  TPP1 0.169 0.2775 
PCDHA2 -0.207 0.21740  SIAH2 -0.168 0.2794 
HTR2B 0.207 0.21764  LRCH4 0.168 0.2795 
ZEB2 -0.207 0.21784  ELK3 0.168 0.2810 
HHIP 0.206 0.22235  ITGB4 0.167 0.2820 
TRAF6 0.206 0.22283  PRPS1 0.166 0.2865 
MYL4 -0.205 0.22319  TFIP11 -0.166 0.2868 
ISL1 -0.205 0.22348  SYK 0.166 0.2872 
SPRY4 0.205 0.22373  AR 0.166 0.2875 
WNT8A -0.205 0.22432  EBP 0.165 0.2877 
HEMGN -0.205 0,22473  PDLIM5 0.165 0.2877 
PCP4 -0.204 0.22835  SPP2 0.166 0.2878 
CREG1 0.203 0.22985  MLL -0.166 0.2879 
MYH6 -0.203 0.23100  MAP2K1 -0.165 0.2880 
SFRP4 0.203 0.23214  LMO4 0.165 0.2888 
HOXA5 0.202 0.23392  HOXA7 0.164 0.2902 
CALCA 0.202 0.23402  KIF1B -0.164 0.2911 
CFDP1 0.201 0.23719  ANGPTL2 0.164 0.2918 
CDON -0.201 0.23834  NRP1 -0.164 0.2920 
ELF3 -0.200 0.24000  UNC5C -0.164 0.2920 
VDR 0.200 0.24100  FGF12 0.163 0.2931 
ID4 0.200 0.24133  RPS6KA3 0.163 0.2931 
NR4A3 0.198 0.24182  MKKS -0.163 0.2933 
GAP43 -0.198 0.24220  LMO2 0.162 0.2936 
E2F1 0.199 0.24239  PPT1 0.161 0.2936 
HOXB8 0.199 0.24251  ERBB3 0.163 0.2937 
MEA1 0.198 0.24276  UBE3A -0.162 0.2937 
AMOT -0.199 0.24276  CHL1 0.163 0.2939 
TMPRSS6 -0.199 0.24283  CYLC1 0.162 0.2940 
DIXDC1 -0.199 0.24293  CYR61 0.162 0.2943 
GREM1 -0.199 0.24305  ENPEP 0.162 0.2945 
DSCAML1 0.199 0.24309  CSRP2 0.162 0.2947 
SPRED1 0.198 0.24326  JAG1 0.162 0.2948 
BMP3 -0.199 0.24358  FEZ1 -0.159 0.2949 
NLGN1 0.199 0.24397  SMAD4 -0.159 0.2949 
PAFAH1B3 0.197 0.24492  GPC3 0.162 0.2949 
RAB23 0.197 0.24627  EMP2 0.159 0.2954 
SEPP1 -0.197 0.24637  FXR1 0.161 0.2955 
IL1RAPL2 -0.196 0.24655  VAMP5 0.161 0.2956 
UNC5B 0.197 0.24671  FBN1 0.159 0.2957 
LDB1 0.196 0.24698  SPRY1 0.159 0.2957 
ACVR1B -0.196 0.24703  SEMA4G 0.161 0.2957 
NPTX1 0.196 0.24768  LGI1 0.159 0.2957 
ODAM 0.196 0.24803  MYH11 0.159 0.2959 
TIMELESS 0.194 0.24989  MAFG -0.161 0.2963 
VEGFC 0.194 0.25038  PLXNA3 -0.159 0.2964 
POSTN 0.194 0.25040  ENPP1 0.158 0.2969 
PAX5 0.194 0.25075  JAG2 -0.159 0.2971 
EBP 0.194 0.25080  UTRN -0.158 0.2972 
FOXO1 -0.195 0.25095  MARK2 -0.159 0.2975 
NFATC3 0.194 0.25102  VCAN 0.160 0.2978 
RPS4X 0.194 0.25125  ARHGAP22 -0.160 0.2978 
GLI2 0.195 0.25142  CYLC2 0.158 0.2982 
FGFR3 -0.195 0.25149  GAMT -0.160 0.2986 
ZNF45 0.194 0.25159  SPIN1 -0.160 0.2988 
ADCYAP1R1 0.195 0.25164  ADAM22 -0.160 0.2988 
FGF13 -0.195 0.25168  NBN 0.160 0.2990 
GADD45G -0.193 0.25180  PITX1 0.157 0.2999 
AVIL -0.193 0.25473     
LGR4 0.192 0.25557     
ROBO3 -0.192 0.25594     
NANOG -0.192 0.25829     
ST6GAL2 0.191 0.26080     
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SVIL 0.191 0.26213     
BDNF 0.190 0.26290     
MTR 0.190 0.26325     
ZEB1 -0.190 0.26433     
LDB2 -0.190 0.26541     
EFNB2 -0.189 0.26886     
SNAI1 0.188 0.27120     
DOK4 -0.188 0.27154     
OBSCN -0.187 0.27476     
ITGB8 -0.188 0.27482     
TOP2B 0.187 0.27491     
PAFAH1B1 -0.186 0.27868     
DGKD -0.186 0.27880     
DVL2 0.186 0.27905     
HAND1 -0.186 0.27917     
GPR56 0.186 0.27919     
EGR2 0.186 0.27944     
ADAM18 -0.186 0.27947     
FGF18 0.186 0.27964     
GNAO1 -0.185 0.28210     
SPG7 -0.185 0.28298     
CHRM1 -0.185 0.28317     
VGLL2 -0.184 0.28560     
CLC -0.184 0.28590     
MKL2 0.184 0.28608     
HLF -0.183 0.28769     
STX2 -0.183 0.28931     
ATP2B2 -0.182 0.29117     
CEBPG 0.182 0.29260     
ID3 0.181 0.29394     
SEMA4C 0.182 0.29444     
CYP46A1 -0.181 0.29458     
ETV4 0.181 0.29479     
POU6F1 -0.181 0.29506     
PHF3 -0.181 0.29570     
HPCAL4 -0.181 0.29581     
BRSK2 -0.180 0.29652     
LGALS3 0.180 0.29692     
PCDHA10 -0.180 0.29782     
AZI1 0.180 0.29806     
EFNB1 0.180 0.29834     
RPL29 0.180 0.29875     
HOXC6 -0.179 0.29904     
LEFTY2 -0.179 0.29926     
 
 
 
 
 
 
 
 
Figure 7.3. mRNA expression of “HIF1Atarget genes” reported as log2 fold change value obtained from rt-
PCR and RNA-seq data analysis. Expression of CDH7, PCDH17, DACH1, LAMA4, SH3RF3, SPON1, TMEM45A, 
GABRB3, KIF26B, PARP-4, SLC35F3 and NAV2 was evaluated by RT-PCR in SKNBE2c sh HIF1A HYP and shCTR 
HYP. The fold-changes of shHIF1A vs shCTR is reported as log2 value.(Y axis). The log2 obtained from RT--PCR 
and from RNA-seq are shown in the graph in black and gray respectively (P-value ≤0.05). For both analysis the same 
mRNA samples (in triplicates) were used. 
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Table 7.3 (Lasorsa VA et al, oncotarget 2016) Results of prioritization of driver mutations combining data obtained 
by WES and DT-seq 
 
 
( MS: missense; SG: stop gain; FI: frameshift insertion; FD: frameshift deletion; II: Inframe Insertion; SS: splicing) 
 In yellow the potential cancer driver genes. 
 
  
Supplementary Table 3c. Results of prioritization of driver mutations combining data obtained by WES and DT-seq
Sample ID Risk group
HUGO 
symbol
Sequence 
ontology
Sequence 
ontology 
protein 
sequence 
change
CHASM 3.2 
cancer 
driver p-
value 
(missense)
CHASM  3.2 
cancer 
driver FDR 
(missense)
VEST 3.2 
pathogenici
ty p-value 
(non-silent)
VEST 3.2 
pathogenici
ty FDR (non-
silent)
Composite 
p-value 
NB1794 HR-Event3 ADCY3 MS C125F 0,3592 0,65 0,0093 0,10
NB1794 HR-Event3 ADCY6 MS G486C 0,0012 0,05 0,0063 0,10
NB2181 HR-Event3 AFF1 MS S466Y 0,0114 0,25 0,0677 0,20
NB2181 HR-Event3 AHNAK FI L5583fs . . 0,0060 0,10
NB2181 HR-Event3 AKAP11 MS E1339G 0,0242 0,35 0,0114 0,10
NB2186 HR-Event3 ALK MS F1174L 0,00001 0,05 0,0116 0,10 8,09E-36
NB1506 HR-Event3 ALK MS F1245V 0,00001 0,05 0,0063 0,10
NB1965 HR-Event3 ALK MS F1245C 0,00001 0,05 0,0060 0,10
NB1229 High ALK MS F1174L 0,00001 0,05 0,0116 0,10
NB1355 Intermediate ALK MS F1174L 0,00001 0,05 0,0116 0,10
KELLY High ALK MS F1174L 0,00001 0,05 0,0116 0,10
LAN-1 High ALK MS F1174L 0,00001 0,05 0,0116 0,10
SK-N-SH High ALK MS F1174L 0,00001 0,05 0,0116 0,10
NB1506 HR-Event3 ALPK1 MS A200T 0,0434 0,45 0,0142 0,10
NB2136 HR-Event3 ANGPTL3 MS L203P 0,0140 0,25 0,0061 0,10
NB2100 HR-Event3 APTX MS H220Q 0,0008 0,05 0,0059 0,10
NB1488 HR-Event3 ARHGEF10L MS W348C 0,2458 0,60 0,0111 0,10 3,28E-04
NB1875 High ARHGEF10L MS G1058D 0,0692 0,50 0,0110 0,10
NB2136 HR-Event3 ASPHD2 MS P174H 0,2390 0,60 0,0138 0,10
NB2181 HR-Event3 ATP8B4 MS Y941C 0,0008 0,05 0,0127 0,10
NB2437 HR-Event3 ATRX SG E1644X 0,0015 0,10 6,84E-03
SK_N_BE2 High ^ATRX MS N717K 0,7476 0,85 0,5182 0,65
NB1488 HR-Event3 CD163 MS G530R 0,0242 0,35 0,0087 0,10
NB2181 HR-Event3 CDIPT MS R55H 0,0158 0,30 0,0062 0,10
NB1506 HR-Event3 CH25H FD 225_226del . . 0,0013 0,10
NB1690 HR-Event3 CHD9 MS S616P 0,00001 0,05 0,0197 0,10 2,54E-11
NB1229 High CHD9 MS F2295L 0,0030 0,10 0,0212 0,10
NB1855 HR-Event3 CHD9 MS R2284G 0,0008 0,05 0,0133 0,10
SK-N-SH High CHD9 MS R2554I 0,0092 0,25 0,0164 0,10
NB2136 HR-Event3 CNNM4 MS A271V 0,1696 0,55 0,0180 0,10
NB1812 HR-Event3 COL5A2 MS R916S 0,3548 0,65 0,0240 0,10
NB2181 HR-Event3 COL6A6 MS G359R 0,0756 0,50 0,0067 0,10 2,11E-06
NB1900 HR-Event3 COL6A6 MS R719Q 0,0042 0,15 0,0120 0,10
CHP126 High COL6A6 MS G1452E 0,1872 0,55 0,0083 0,10
NB1690 HR-Event3 COLGALT2 MS R196L 0,0148 0,25 0,0079 0,10
NB2181 HR-Event3 CPLX2 MS M55I 0,0932 0,55 0,0197 0,10
NB2181 HR-Event3 CTNNAL1 MS A420T 0,1382 0,55 0,0195 0,10
NB2181 HR-Event3 DCHS1 MS R2330C 0,2138 0,60 0,0183 0,10
NB2136 HR-Event3 DCUN1D4 MS E246K 0,0242 0,35 0,0056 0,10
NB1995 HR-Event3 DHRS7 MS R271G 0,2830 0,60 0,0172 0,10
NB2161 HR-Event3 DMBT1 SG S542X . . 0,0060 0,10
NB1794 HR-Event3 DTHD1 MS I405K 0,1098 0,55 0,0067 0,10 2,16E-04
NB1054 HR-Event3 DTHD1 MS P489T 0,2000 0,60 0,0118 0,10
NB1488 HR-Event3 DYSF MS L2R 0,2390 0,60 0,0225 0,10
NB1488 HR-Event3 ERBB3 MS C231Y 0,0056 0,15 0,0065 0,10
NB2100 HR-Event3 FGFR1 MS N457K 0,0000 0,05 0,1207 0,30
NB1690 HR-Event3 FHOD3 MS R1388L 0,0148 0,25 0,0284 0,15
NB1488 HR-Event3 FZD1 MS Q572L 0,1668 0,55 0,0176 0,10 6,84E-04
NB2794 HR-Event3 FZD1 SG E314X 0,0152 0,10
NB1488 HR-Event3 FZD7 MS Y244H 0,0392 0,40 0,0108 0,10
NB1914 HR-Event3 GABRB2 MS F464L 0,2050 0,60 0,0084 0,10 1,47E-04
LAN-1 High GABRB2 MS R354S 0,0326 0,40 0,0062 0,10
NB2136 HR-Event3 GBE1 MS P440T 0,0058 0,15 0,0080 0,10 2,35E-04
CHP126 High GBE1 MS P552L 0,0146 0,25 0,0106 0,10
NB1812 HR-Event3 GCNT4 MS P132Q 0,1524 0,55 0,0086 0,10
NB1794 HR-Event3 HADHB MS D357Y 0,0604 0,50 0,0069 0,10
NB2181 HR-Event3 HECTD3 MS R406C 0,0400 0,40 0,0106 0,10
NB1767 HR-Event3 HIVEP1 MS R1029I 0,1872 0,55 0,0154 0,10
NB2136 HR-Event3 HNF4A MS G79S 0,2116 0,60 0,0066 0,10
NB2136 HR-Event3 HTRA1 MS A180T 0,0406 0,40 0,0199 0,10 4,21E-06
NB962 HR-Event3 HTRA1 FD 171_171del 0,0010 0,10
STA-N-B7 High HTRA1 MS R197Q 0,1078 0,55 0,0190 0,10
NB1488 HR-Event3 IKBKAP MS G1210D 0,0008 0,05 0,0065 0,10
NB2181 HR-Event3 INTS1 MS F1962C 0,3258 0,65 0,0231 0,10
NB1488 HR-Event3 IPO5 MS E1026K 0,0000 0,05 0,0065 0,10 5,03E-08
NB2122 HR-Event3 IPO5 MS D251N 0,0010 0,05 0,2404 0,40
NB1488 HR-Event3 ITSN1 MS N1399D 0,0092 0,25 0,2845 0,45
NB2186 HR-Event3 KAT8 FI Q234fs . . 0,0009 0,10
NB1952 HR-Event3 KCNK18 MS E305K 0,0216 0,35 0,0057 0,10
NB2181 HR-Event3 KCTD10 MS G198R 0,1148 0,55 0,0076 0,10
NB2181 HR-Event3 KDM1B MS V391A 0,0552 0,45 0,0183 0,10
NB2181 HR-Event3 L1CAM MS R750H 0,0008 0,05 0,0101 0,10
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